|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression decreases expression multiple interactions |
ISO |
Lovastatin results in increased expression of ABCA1 mRNA lovastatin decreases expression of ABCA1 mRNA in HepG2 cells [Dietary Fats co-treated with Lovastatin] affects the expression of ABCA1 mRNA Lovastatin results in decreased expression of ABCA1 mRNA |
CTD RGD |
PMID:19260826 PMID:29852127 PMID:27765770 |
RGD:18936994 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Lovastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Lovastatin results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases activity increases transport |
ISO |
Lovastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] Lovastatin analog results in decreased activity of ABCB1 protein ABCB1 protein results in increased transport of Lovastatin; ABCB1 protein results in increased transport of Lovastatin analog |
CTD |
PMID:15616150 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity multiple interactions |
ISO |
Lovastatin results in decreased activity of ABCC1 protein [Lovastatin results in decreased activity of ABCC1 protein] which results in increased susceptibility to Antimony Sodium Gluconate; Doxorubicin inhibits the reaction [Lovastatin results in increased expression of ABCC1 mRNA] |
CTD |
PMID:18056276 PMID:22712078 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression decreases activity |
ISO EXP |
ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Lovastatin results in increased expression of ABCC2 mRNA Lovastatin analog results in decreased activity of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Lovastatin analog; Lovastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Lovastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM]; Lovastatin promotes the reaction [Cisplatin results in decreased expression of ABCC2 mRNA] |
CTD |
PMID:15616150 PMID:23562342 PMID:26739623 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of ABCG5 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ABCG5 mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
affects expression |
ISO |
Lovastatin affects the expression of ABCG8 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACACA mRNA |
CTD |
PMID:29852127 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACOX1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of ACSS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] Lovastatin results in decreased expression of ACTA2 protein |
CTD |
PMID:22129737 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of ACTB mRNA Lovastatin results in increased expression of ACTB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actr3 |
actin related protein 3 |
increases expression |
ISO |
Lovastatin results in increased expression of ACTR3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Adam10 |
ADAM metallopeptidase domain 10 |
increases expression multiple interactions |
EXP ISO |
Lovastatin results in increased expression of ADAM10 protein [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein |
CTD |
PMID:29341888 |
|
NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of ADIPOQ mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of ADIPOQ mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO |
Lovastatin results in decreased expression of AHCY mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
decreases response to substance |
ISO |
AKAP7 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of AKT1 protein] Lovastatin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16425225 PMID:17472962 PMID:19760159 PMID:20578043 PMID:35734936 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased activity of ALOX15 protein] |
CTD |
PMID:35734936 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Ank2 |
ankyrin 2 |
decreases response to substance |
ISO |
ANK2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Anxa4 |
annexin A4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ANXA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Anxa5 |
annexin A5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ANXA5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Lovastatin co-treated with Niacin] results in increased expression of APOA1 protein; [Niacin co-treated with Lovastatin] results in increased expression of APOA1 protein |
CTD |
PMID:12633795 PMID:17319473 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apob |
apolipoprotein B |
multiple interactions decreases secretion |
ISO |
[Niacin co-treated with Lovastatin] results in decreased expression of APOB protein Lovastatin results in decreased secretion of APOB protein |
CTD |
PMID:11728391 PMID:12633795 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of APOE mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of APOE mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases cleavage increases secretion |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; TAPI-2 inhibits the reaction [Lovastatin results in increased secretion of APP protein modified form]; U 0126 inhibits the reaction [Lovastatin results in increased secretion of APP protein] [APP protein co-treated with Lovastatin] results in increased secretion of APP protein; [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein; [Lovastatin co-treated with APP protein] results in increased expression of ADAM10 protein; [Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein; [Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[APP protein co-treated with Lovastatin] results in increased secretion of APP protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased cleavage of APP protein Lovastatin results in increased secretion of APP protein; Lovastatin results in increased secretion of APP protein modified form |
CTD |
PMID:19741129 PMID:29341888 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Lovastatin results in increased expression of ARHGDIA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATM protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of ATR protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bace1 |
beta-secretase 1 |
decreases expression multiple interactions |
EXP ISO |
Lovastatin results in decreased expression of BACE1 protein [Lovastatin co-treated with APP protein] results in decreased expression of BACE1 protein |
CTD |
PMID:29341888 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bace2 |
beta-secretase 2 |
multiple interactions increases expression |
ISO EXP |
[Lovastatin co-treated with APP protein] results in increased expression of BACE2 protein Lovastatin results in increased expression of BACE2 protein |
CTD |
PMID:29341888 |
|
NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions affects localization |
ISO EXP |
Lovastatin results in increased expression of BAX protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BAX protein]; Lovastatin promotes the reaction [Cisplatin results in increased expression of BAX mRNA] Lovastatin affects the localization of BAX protein |
CTD |
PMID:10473109 PMID:15180944 PMID:26739623 PMID:35734936 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases cleavage multiple interactions |
EXP |
Lovastatin results in increased cleavage of BCAR1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of BCAR1 protein] |
CTD |
PMID:16367743 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased expression of BCL2 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2 protein] |
CTD |
PMID:10473109 PMID:11178870 PMID:12094262 PMID:35734936 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
EXP |
Lovastatin results in decreased expression of BCL2L1 protein Mevalonic Acid inhibits the reaction [Lovastatin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:11178870 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein] |
CTD |
PMID:18766339 PMID:35734936 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased expression of BDNF protein] |
CTD |
PMID:24718106 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in decreased expression of BIRC5 protein] |
CTD |
PMID:17472962 PMID:18815881 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of BRCA2 mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
C1qbp |
complement C1q binding protein |
increases expression |
ISO |
Lovastatin results in increased expression of C1QBP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649
|
|
G |
Calr |
calreticulin |
increases expression |
ISO |
Lovastatin results in increased expression of CALR mRNA |
CTD |
PMID:20493250 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2b |
calcium/calmodulin-dependent protein kinase II beta |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of CAMK2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr14:80,845,206...80,934,172
Ensembl chr14:80,845,238...80,933,994
|
|
G |
Casp2 |
caspase 2 |
increases activity multiple interactions |
ISO |
Lovastatin results in increased activity of CASP2 protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] |
CTD |
PMID:12933658 PMID:16234849 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] Lovastatin analog results in increased cleavage of CASP3 protein Lovastatin results in increased activity of CASP3 protein Lovastatin results in decreased expression of CASP3 mRNA Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CASP3 protein]; Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased activity of and results in increased cleavage of CASP3 protein] |
CTD |
PMID:11720884 PMID:12933658 PMID:15180944 PMID:16367743 PMID:18034278 PMID:18766339 PMID:20493250 PMID:26863638 PMID:35734936 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
increases activity |
ISO |
Lovastatin results in increased activity of CASP6 protein |
CTD |
PMID:11720884 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Lovastatin results in increased activity of CASP8 protein |
CTD |
PMID:15180944 PMID:15705602 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
Lovastatin results in increased activity of CASP9 protein Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased expression of CASP9 protein] |
CTD |
PMID:12933658 PMID:15180944 PMID:15705602 PMID:35734936 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in decreased activity of CAT protein] |
CTD |
PMID:35734936 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CCN2 mRNA]; Lovastatin inhibits the reaction [Epirubicin results in increased expression of CCN2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression increases expression |
ISO EXP |
Lovastatin results in decreased expression of CCND1 protein Lovastatin results in increased expression of CCND1 mRNA; Lovastatin results in increased expression of CCND1 protein |
CTD |
PMID:18034278 PMID:20578043 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CCND3 protein |
CTD |
PMID:10502407 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Cct5 |
chaperonin containing TCP1 subunit 5 |
increases expression |
ISO |
Lovastatin results in increased expression of CCT5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:82,591,750...82,602,903
Ensembl chr 2:82,590,630...82,602,930
|
|
G |
Cct6a |
chaperonin containing TCP1 subunit 6A |
increases expression |
ISO |
Lovastatin results in increased expression of CCT6A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:26,872,736...26,883,125
Ensembl chr12:26,872,574...26,883,337
|
|
G |
Cct8 |
chaperonin containing TCP1 subunit 8 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CCT8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr11:26,710,370...26,722,079
Ensembl chr11:26,710,370...26,722,079
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
decreases expression |
ISO |
Lovastatin results in decreased expression of CD44 mRNA; Lovastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cdc42 |
cell division cycle 42 |
increases expression decreases expression |
ISO |
Lovastatin results in increased expression of CDC42 protein Lovastatin results in decreased expression of CDC42 mRNA |
CTD |
PMID:18766339 PMID:20493250 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CDK2 protein |
CTD |
PMID:10502407 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
EXP |
Lovastatin results in decreased expression of CDK4 mRNA; Lovastatin results in decreased expression of CDK4 protein |
CTD |
PMID:20578043 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases cleavage |
EXP |
Lovastatin results in decreased cleavage of CDK5 protein |
CTD |
PMID:19741129 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of CDKN1A protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CDKN1A mRNA] |
CTD |
PMID:18034278 PMID:22712078 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
EXP ISO |
Lovastatin results in increased expression of CDKN1B mRNA; Lovastatin results in increased expression of CDKN1B protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 PMID:18034278 PMID:20578043 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CDKN3 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cenpf |
centromere protein F |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of CENPF protein Lovastatin promotes the reaction [Paclitaxel results in increased expression of CENPF protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of CENPF protein] |
CTD |
PMID:12467231 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cfl1 |
cofilin 1 |
decreases phosphorylation |
EXP |
Lovastatin results in decreased phosphorylation of CFL1 protein |
CTD |
PMID:20578043 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of CHEK1 protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of CHEK1 protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK1 protein modified form] |
CTD |
PMID:17088865 PMID:21356574 PMID:26739623 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of CHEK2 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions increases expression |
ISO EXP |
[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased expression of CHRNA7 protein] Lovastatin results in increased expression of CHRNA7 mRNA; Lovastatin results in increased expression of CHRNA7 protein U 0126 inhibits the reaction [Lovastatin results in increased expression of CHRNA7 protein] |
CTD |
PMID:29341888 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of CLIC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
increases expression |
ISO |
Lovastatin results in increased expression of COX5A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CP protein] |
CTD |
PMID:35734936 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crk |
CRK proto-oncogene, adaptor protein |
increases expression |
ISO |
Lovastatin results in increased expression of CRK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,530,469...60,556,703
Ensembl chr10:60,530,464...60,553,406
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of CRP protein] |
CTD |
PMID:35734936 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases degradation increases expression multiple interactions |
EXP ISO |
Lovastatin results in decreased degradation of CTNNB1 protein Lovastatin results in increased expression of CTNNB1 mRNA Lovastatin affects the localization of and results in increased expression of CTNNB1 protein |
CTD |
PMID:17234346 PMID:19741129 PMID:24742230 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of CYP1A1 mRNA]; Lovastatin results in increased expression of and results in increased activity of CYP1A1 protein Lovastatin results in increased expression of CYP1A1 mRNA |
CTD |
PMID:1311272 PMID:22712078 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Lovastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Lovastatin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:12505310 PMID:17041008 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dctn2 |
dynactin subunit 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of DCTN2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:63,092,061...63,107,560
Ensembl chr 7:63,092,057...63,108,543
|
|
G |
Ddt |
D-dopachrome tautomerase |
decreases expression |
ISO |
Lovastatin results in decreased expression of DDT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482
|
|
G |
Dlg3 |
discs large MAGUK scaffold protein 3 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of DLG3 protein] |
CTD |
PMID:24718106 |
|
NCBI chr X:65,859,653...65,911,887
Ensembl chr X:65,860,172...65,910,322
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
decreases expression |
ISO |
Lovastatin results in decreased expression of DLST mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dock7 |
dedicator of cytokinesis 7 |
increases expression |
ISO |
Lovastatin results in increased expression of DOCK7 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:113,599,371...113,782,871
Ensembl chr 5:113,600,198...113,782,813
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
ISO |
Lovastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
decreases expression |
ISO |
Lovastatin results in decreased expression of DSTN mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases response to substance |
ISO |
EAF2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of EEF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [EGF protein promotes the reaction [EGFR protein results in increased phosphorylation of EGFR protein]]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:12942316 PMID:19760159 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif3i |
eukaryotic translation initiation factor 3, subunit I |
decreases expression |
ISO |
Lovastatin results in decreased expression of EIF3I mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,935,135...141,942,589
Ensembl chr 5:141,935,044...141,942,676
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression multiple interactions |
EXP |
Lovastatin results in increased expression of ERCC1 mRNA Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC1 mRNA] |
CTD |
PMID:26739623 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions increases expression |
EXP |
Lovastatin promotes the reaction [Cisplatin results in increased expression of ERCC5 mRNA] Lovastatin results in increased expression of ERCC5 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases expression |
EXP |
Lovastatin results in increased expression of ERCC6 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
Erp29 |
endoplasmic reticulum protein 29 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ERP29 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
|
|
G |
Fads2 |
fatty acid desaturase 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FADS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FAS mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of FAS protein] |
CTD |
PMID:17088865 PMID:35734936 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FASLG mRNA] |
CTD |
PMID:17088865 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
Lovastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein]; Lovastatin promotes the reaction [Fenofibrate results in increased expression of FBXO32 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 mRNA]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of FBXO32 protein] Lovastatin results in increased expression of FBXO32 mRNA; Lovastatin results in increased expression of FBXO32 protein |
CTD |
PMID:19406843 PMID:33408297 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases activity |
ISO |
Lovastatin results in increased activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FDPS mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions decreases expression |
EXP ISO |
Lovastatin affects the expression of FOS protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of FOS mRNA] Lovastatin results in decreased expression of FOS |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased expression of FOSB protein] |
CTD |
PMID:18434508 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
ISO |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of FOXO1 protein] Lovastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 PMID:33408297 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of FSCN1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
G3bp1 |
G3BP stress granule assembly factor 1 |
increases expression |
ISO |
Lovastatin results in increased expression of G3BP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:39,586,864...39,620,268
Ensembl chr10:39,586,864...39,620,268
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of G6PD mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gale |
UDP-galactose-4-epimerase |
decreases expression |
ISO |
Lovastatin results in decreased expression of GALE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Gap43 |
growth associated protein 43 |
increases expression |
ISO |
Lovastatin results in increased expression of GAP43 protein |
CTD |
PMID:20694854 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
increases expression |
ISO |
Lovastatin results in increased expression of GDI2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of GK mRNA |
CTD |
PMID:29852127 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gmps |
guanine monophosphate synthase |
increases expression |
ISO |
Lovastatin results in increased expression of GMPS mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of GPT protein; Lovastatin inhibits the reaction [Dietary Fats results in increased expression of GPT protein] |
CTD |
PMID:29852127 PMID:30853469 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of GPX1 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of GRIN2B protein] |
CTD |
PMID:24718106 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation increases phosphorylation |
ISO EXP |
Lovastatin results in decreased phosphorylation of GSK3B protein Lovastatin results in increased phosphorylation of GSK3B protein |
CTD |
PMID:17234346 PMID:19741129 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form] Lovastatin inhibits the reaction [Cisplatin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of H2AX protein modified form]; Lovastatin inhibits the reaction [Doxorubicin results in increased phosphorylation of H2AX protein] |
CTD |
PMID:21356574 PMID:22712078 PMID:26739623 PMID:28710503 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hdac1 |
histone deacetylase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HDAC1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HINT1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions affects expression decreases activity increases expression |
ISO |
[Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of farnesyl pyrophosphate; [Lovastatin results in decreased activity of HMGCR protein] which results in decreased abundance of geranylgeranyl pyrophosphate; Lovastatin inhibits the reaction [HMGCR protein results in increased abundance of geranyl diphosphate] [Dietary Fats co-treated with Lovastatin] affects the expression of HMGCR mRNA Lovastatin affects the expression of HMGCR mRNA Lovastatin results in increased expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:17208200 PMID:19260826 PMID:19699819 PMID:19856009 PMID:27208389 PMID:29852127 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of HMGCS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of HMOX1 protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of HMOX1 mRNA] |
CTD |
PMID:20594940 PMID:21910007 PMID:28710503 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpab |
heterogeneous nuclear ribonucleoprotein A/B |
increases expression |
ISO |
Lovastatin results in increased expression of HNRNPAB mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:35,857,040...35,862,935
Ensembl chr10:35,857,041...35,863,344
|
|
G |
Hnrnpdl |
heterogeneous nuclear ribonucleoprotein D-like |
decreases expression |
ISO |
Lovastatin results in decreased expression of HNRNPDL mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:9,557,430...9,563,659
Ensembl chr14:9,557,425...9,562,506
|
|
G |
Hnrnpf |
heterogeneous nuclear ribonucleoprotein F |
increases expression |
ISO |
Lovastatin results in increased expression of HNRNPF mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:151,083,262...151,104,464
Ensembl chr 4:151,083,062...151,109,038
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of HNRNPK mRNA Lovastatin results in increased expression of HNRNPK mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
decreases prenylation multiple interactions |
ISO |
Lovastatin results in decreased prenylation of HRAS protein Lovastatin results in decreased prenylation of and results in decreased localization of HRAS protein |
CTD |
PMID:16156861 PMID:19360310 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
Lovastatin results in increased expression of HSPA8 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
Lovastatin results in increased expression of HSPD1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases response to substance |
ISO |
IGF1 protein results in decreased susceptibility to Lovastatin |
CTD |
PMID:9525472 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
EXP |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:19741129 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] |
CTD |
PMID:21430599 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]; tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] |
CTD |
PMID:18809656 PMID:21430599 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein] |
CTD |
PMID:28710503 PMID:35734936 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of IGF1R protein]; Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insig1 |
insulin induced gene 1 |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of INSIG1 mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of INSIG1 mRNA |
CTD |
PMID:19260826 PMID:29852127 |
|
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
|
|
G |
Insig2 |
insulin induced gene 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of INSIG2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
Lovastatin promotes the reaction [INS protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:19741129 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Ipo5 |
importin 5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of IPO5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr15:97,990,755...98,041,074
Ensembl chr15:98,005,299...98,041,126
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of IRF4 protein |
CTD |
PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of IRS2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Isyna1 |
inositol-3-phosphate synthase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of ISYNA1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:12405293 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression multiple interactions decreases expression |
EXP ISO |
Lovastatin affects the expression of JUN protein Lovastatin inhibits the reaction [Doxorubicin results in increased expression of JUN mRNA] Lovastatin results in decreased expression of JUN |
CTD |
PMID:10412747 PMID:12392621 PMID:22712078 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
Lovastatin affects the activity of KCNH2 protein |
CTD |
PMID:16278312 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases prenylation increases expression affects localization increases activity |
ISO |
Lovastatin results in decreased prenylation of KRAS protein Lovastatin results in increased expression of KRAS protein Lovastatin affects the localization of KRAS protein Lovastatin results in increased activity of KRAS protein |
CTD |
PMID:12106604 PMID:12907238 PMID:16156861 PMID:17005160 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Krt18 |
keratin 18 |
decreases expression |
ISO |
Lovastatin results in decreased expression of KRT18 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Lasp1 |
LIM and SH3 protein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of LASP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of LCN2 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases activity increases expression |
ISO EXP |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of LDLR mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased expression of LDLR mRNA] Lovastatin results in increased activity of LDLR protein |
CTD |
PMID:8593127 PMID:11728391 PMID:12524230 PMID:20578043 PMID:29852127 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
affects localization |
ISO |
Lovastatin affects the localization of LEF1 protein |
CTD |
PMID:17234346 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lipc |
lipase C, hepatic type |
affects expression |
ISO |
Lovastatin affects the expression of LIPC mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lmnb1 |
lamin B1 |
decreases farnesylation increases degradation affects localization |
ISO |
Lovastatin results in decreased farnesylation of LMNB1 protein Lovastatin results in increased degradation of LMNB1 protein Lovastatin affects the localization of LMNB1 protein |
CTD |
PMID:10203554 PMID:11720884 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Lpin2 |
lipin 2 |
decreases response to substance |
ISO |
LPIN2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 9:111,083,378...111,158,193
Ensembl chr 9:111,083,745...111,158,193
|
|
G |
Lpl |
lipoprotein lipase |
affects expression multiple interactions |
ISO |
Lovastatin affects the expression of LPL mRNA [Dietary Fats co-treated with Lovastatin] affects the expression of LPL mRNA |
CTD |
PMID:27208389 PMID:29852127 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
increases expression |
ISO |
Lovastatin results in increased expression of LRP5 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation decreases activity decreases phosphorylation |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK1 protein]; Lovastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of MAPK1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK1 protein] Lovastatin results in decreased activity of MAPK1 protein [Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK1 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12213976 PMID:16952276 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation decreases activity decreases phosphorylation |
ISO EXP |
[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of APP protein]; Lovastatin affects the reaction [[MAPK3 protein co-treated with APP protein] affects the expression of CHRNA7 protein]; Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [[Lovastatin co-treated with APP protein] results in increased phosphorylation of MAPK3 protein] Lovastatin results in increased phosphorylation of MAPK3 protein Lovastatin results in decreased activity of MAPK3 protein Lovastatin results in decreased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in decreased phosphorylation of MAPK3 protein]; Lovastatin inhibits the reaction [benserazide, levodopa drug combination results in increased phosphorylation of MAPK3 protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in decreased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Lovastatin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16952276 PMID:18434508 PMID:19360310 PMID:19760159 PMID:20578043 PMID:24718106 PMID:29341888 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK8 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cisplatin results in increased expression of MAPK9 protein modified form] |
CTD |
PMID:26739623 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mbp |
myelin basic protein |
multiple interactions increases expression |
EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MFN2 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir133b |
microRNA 133b |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR133B mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 9:23,098,134...23,098,217
Ensembl chr 9:23,098,134...23,098,217
|
|
G |
Mir206 |
microRNA 206 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of MIR206 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:23,094,249...23,094,332
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of MMP2 protein |
CTD |
PMID:19360310 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of MMP3 mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
ISO |
Lovastatin results in decreased expression of MMP9 protein |
CTD |
PMID:19360310 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MPO protein] |
CTD |
PMID:35734936 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Lovastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
Doxorubicin inhibits the reaction [Lovastatin results in increased expression of NFE2L2 mRNA]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:22712078 PMID:28710503 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nmral1 |
NmrA like redox sensor 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NMRAL1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein] |
CTD |
PMID:18809656 PMID:35734936 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of NPPA mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NQO1 mRNA |
CTD |
PMID:1311272 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
[Lovastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17041008 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
decreases prenylation |
ISO |
Lovastatin results in decreased prenylation of NRAS protein |
CTD |
PMID:16156861 |
|
NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
|
|
G |
Nucb1 |
nucleobindin 1 |
increases expression |
ISO |
Lovastatin results in increased expression of NUCB1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,968,325...95,999,183
Ensembl chr 1:95,968,326...96,003,220
|
|
G |
Oat |
ornithine aminotransferase |
decreases expression |
ISO |
Lovastatin results in decreased expression of OAT mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
OSM protein promotes the reaction [Lovastatin results in increased expression of LDLR mRNA] |
CTD |
PMID:12524230 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Pa2g4 |
proliferation-associated 2G4 |
increases expression |
ISO |
Lovastatin results in increased expression of PA2G4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:984,795...992,264
Ensembl chr 7:983,971...992,331
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Lovastatin analog results in increased cleavage of PARP1 protein |
CTD |
PMID:26863638 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Parvb |
parvin, beta |
decreases response to substance |
ISO |
PARVB SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:115,360,261...115,445,766
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of PCK1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
EXP |
Lovastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:20578043 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdia3 |
protein disulfide isomerase family A, member 3 |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of PDIA3 mRNA Lovastatin results in increased expression of PDIA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236
|
|
G |
Pdia4 |
protein disulfide isomerase family A, member 4 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PDIA4 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:76,803,198...76,822,245
Ensembl chr 4:76,803,198...76,822,107
|
|
G |
Pgam1 |
phosphoglycerate mutase 1 |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of PGAM1 mRNA Lovastatin results in increased expression of PGAM1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:240,723,832...240,731,443
Ensembl chr 1:240,723,920...240,738,452
|
|
G |
Pkm |
pyruvate kinase M1/2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PKM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
increases expression |
EXP |
Lovastatin results in increased expression of PLA2G4A mRNA |
CTD |
PMID:20578043 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions increases secretion increases expression |
EXP ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PLAT protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PLAT protein] Lovastatin results in increased secretion of PLAT protein |
CTD |
PMID:10412747 PMID:12405293 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases secretion |
ISO |
Lovastatin results in decreased secretion of PLAU protein |
CTD |
PMID:12405293 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pon3 |
paraoxonase 3 |
increases hydrolysis increases metabolic processing multiple interactions |
ISO |
PON3 protein results in increased hydrolysis of Lovastatin PON3 protein results in increased metabolism of Lovastatin 7-ketocholesterol inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin]; Phosphatidylcholines inhibits the reaction [PON3 protein results in increased metabolism of Lovastatin] |
CTD |
PMID:12615656 PMID:15772423 |
|
NCBI chr 4:33,356,983...33,383,681
Ensembl chr 4:33,349,168...33,383,855
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions affects localization increases expression |
ISO EXP |
2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lovastatin analog affects the localization of PPARG protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; Lovastatin results in increased expression of and affects the localization of PPARG protein; Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of PPARG mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] [Dietary Fats co-treated with Lovastatin] affects the expression of PPARG mRNA; PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 PMID:26863638 PMID:29852127 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:28710503 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Lovastatin results in decreased expression of PPP1CA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
increases expression |
ISO |
Lovastatin results in increased expression of PPP2R1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions increases cleavage |
EXP |
benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein]; Mevalonic Acid inhibits the reaction [Lovastatin results in increased cleavage of PRKCD protein] |
CTD |
PMID:16367743 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Psma3 |
proteasome 20S subunit alpha 3 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMA3 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:89,483,741...89,503,775
Ensembl chr 6:89,483,727...89,504,965
|
|
G |
Psma6 |
proteasome 20S subunit alpha 6 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMA6 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 6:72,765,534...72,796,554
Ensembl chr 6:72,765,473...72,796,554
|
|
G |
Psmc2 |
proteasome 26S subunit, ATPase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of PSMC2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO EXP |
Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; PPARG protein affects the reaction [Lovastatin results in increased expression of PTEN protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of PTEN mRNA]; Lovastatin results in increased expression of and results in increased phosphorylation of PTEN protein; PTEN protein affects the reaction [Lovastatin results in increased expression of MBP mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] PPARG affects the reaction [Lovastatin results in increased expression of PTEN protein] |
CTD |
PMID:16425225 PMID:20578043 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression increases expression multiple interactions |
ISO EXP |
Lovastatin results in decreased expression of PTGS2 protein Lovastatin analog results in increased expression of PTGS2 mRNA; Lovastatin analog results in increased expression of PTGS2 protein Mevalonic Acid affects the reaction [Lovastatin analog results in increased expression of PTGS2 protein] Lovastatin results in increased expression of PTGS2 mRNA; Lovastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20578043 PMID:21910007 PMID:26863638 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab1a |
RAB1A, member RAS oncogene family |
decreases expression |
ISO |
Lovastatin results in decreased expression of RAB1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions affects localization decreases activity increases expression |
ISO |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RAC1 protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RAC1 protein] Lovastatin results in decreased activity of RAC1 protein Lovastatin results in increased expression of RAC1 protein |
CTD |
PMID:12933658 PMID:18766339 PMID:19360310 PMID:21356574 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions decreases activity |
ISO |
Lovastatin inhibits the reaction [EGF protein results in increased phosphorylation of RAF1 protein] Lovastatin results in decreased activity of RAF1 protein |
CTD |
PMID:19360310 PMID:19760159 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases expression |
ISO |
Lovastatin results in increased expression of RAP1A protein |
CTD |
PMID:12467231 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
EXP ISO |
Lovastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:9848777 PMID:10502407 PMID:15118409 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases expression decreases prenylation affects localization |
ISO EXP |
geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Lovastatin affects the localization of RHOA protein] Lovastatin results in decreased geranoylation of and affects the localization of RHOA protein Lovastatin results in decreased expression of RHOA mRNA Lovastatin results in decreased prenylation of RHOA protein Farnesol inhibits the reaction [Lovastatin affects the localization of RHOA protein]; geranylgeraniol inhibits the reaction [Lovastatin affects the localization of RHOA protein] |
CTD |
PMID:9398081 PMID:11178870 PMID:12405293 PMID:12933658 PMID:16156861 PMID:20493250 PMID:20578043 More...
|
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhob |
ras homolog family member B |
decreases prenylation multiple interactions increases expression |
ISO |
Lovastatin results in decreased prenylation of RHOB protein Lovastatin promotes the reaction [RHOB protein binds to CASP2 protein] Lovastatin results in increased expression of RHOB protein |
CTD |
PMID:12467231 PMID:16156861 PMID:16234849 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rpl27 |
ribosomal protein L27 |
increases expression |
ISO |
Lovastatin results in increased expression of RPL27 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193
|
|
G |
Rpl9 |
ribosomal protein L9 |
increases expression |
ISO |
Lovastatin results in increased expression of RPL9 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136 Ensembl chr 3:42,893,942...42,897,136
|
|
G |
Rplp0 |
ribosomal protein lateral stalk subunit P0 |
increases expression |
ISO |
Lovastatin results in increased expression of RPLP0 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr12:41,054,363...41,057,632
Ensembl chr12:41,054,179...41,057,632
|
|
G |
Rpsa |
ribosomal protein SA |
increases expression |
ISO |
Lovastatin results in increased expression of RPSA mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Ruvbl2 |
RuvB-like AAA ATPase 2 |
decreases expression |
ISO |
Lovastatin results in decreased expression of RUVBL2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:95,902,014...95,915,247
Ensembl chr 1:95,901,701...95,915,342
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A8 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[Buthionine Sulfoximine co-treated with Lovastatin co-treated with Gemfibrozil] results in increased expression of S100A9 mRNA |
CTD |
PMID:30853469 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sae1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of SAE1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986
|
|
G |
Scap |
SREBF chaperone |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCAP mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions affects expression |
ISO |
[Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone] Lovastatin affects the expression of SCARB1 mRNA |
CTD |
PMID:20404351 PMID:27208389 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SCD1 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sephs1 |
selenophosphate synthetase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of SEPHS1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593
|
|
G |
Slc31a1 |
solute carrier family 31 member 1 |
increases expression |
EXP |
Lovastatin results in increased expression of SLC31A1 mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 5:75,814,744...75,844,241
Ensembl chr 5:75,814,743...75,844,228
|
|
G |
Sox10 |
SRY-box transcription factor 10 |
multiple interactions increases expression |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PPARG protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA]; PTEN protein affects the reaction [Lovastatin results in increased expression of SOX10 mRNA] |
CTD |
PMID:20578043 |
|
NCBI chr 7:110,725,274...110,734,651
Ensembl chr 7:110,725,274...110,735,544
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions increases expression |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of SREBF1 mRNA Lovastatin results in increased expression of SREBF1 mRNA |
CTD |
PMID:29852127 PMID:32739440 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
increases localization multiple interactions |
ISO EXP |
Lovastatin results in increased localization of SREBF2 protein [Dietary Fats co-treated with Lovastatin] affects the expression of SREBF2 mRNA [Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein; Cholesterol inhibits the reaction [[Cholesterol deficiency co-treated with Lovastatin] results in increased activity of SREBF2 protein] |
CTD |
PMID:11728391 PMID:20578043 PMID:29852127 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Steap2 |
STEAP2 metalloreductase |
decreases response to substance |
ISO |
STEAP2 SNP results in decreased susceptibility to Lovastatin |
CTD |
PMID:21483694 |
|
NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Lovastatin results in decreased expression of STIP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Syngap1 |
synaptic Ras GTPase activating protein 1 |
multiple interactions |
EXP |
Lovastatin inhibits the reaction [[Oxygen deficiency co-treated with Carbon Dioxide] results in increased expression of SYNGAP1 protein] |
CTD |
PMID:24718106 |
|
NCBI chr20:5,026,366...5,056,659
Ensembl chr20:5,026,364...5,056,672
|
|
G |
Tcp1 |
t-complex 1 |
increases expression |
ISO |
Lovastatin results in increased expression of TCP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:47,829,061...47,836,809
Ensembl chr 1:47,828,652...47,836,839
|
|
G |
Tg |
thyroglobulin |
increases secretion |
ISO |
Lovastatin results in increased secretion of TG protein |
CTD |
PMID:12843138 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [TGFB1 protein results in increased abundance of Reactive Oxygen Species]; Lovastatin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:22129737 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
increases expression multiple interactions |
ISO |
Lovastatin results in increased expression of TH protein Mevalonic Acid inhibits the reaction [Lovastatin results in increased expression of TH protein] |
CTD |
PMID:20694854 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thop1 |
thimet oligopeptidase 1 |
increases expression |
ISO |
Lovastatin results in increased expression of THOP1 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:8,632,911...8,645,339
Ensembl chr 7:8,632,916...8,645,275
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein; geraniol inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; geraniol promotes the reaction [tipifarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]; Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Lovastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; manumycin inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein] Lovastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein] |
CTD |
PMID:18809656 PMID:21430599 PMID:22712078 PMID:35734936 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
Lovastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:24742230 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
Lovastatin results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:17928957 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
Lovastatin results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:24742230 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TOP2A mRNA] |
CTD |
PMID:22712078 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; Lovastatin results in increased expression of and results in increased phosphorylation of TP53 protein Lovastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein modified form] Lovastatin results in increased expression of TP53 mRNA |
CTD |
PMID:17088865 PMID:21199873 PMID:26739623 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trim63 |
tripartite motif containing 63 |
multiple interactions |
ISO |
Lovastatin promotes the reaction [Fenofibrate results in increased expression of TRIM63 protein] |
CTD |
PMID:33408297 |
|
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
|
|
G |
Ttc7a |
tetratricopeptide repeat domain 7A |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of FSN mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 6:7,159,285...7,261,826
Ensembl chr 6:7,159,061...7,261,892
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
ISO |
Lovastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tuba1b |
tubulin, alpha 1B |
increases expression decreases expression |
ISO |
Lovastatin results in increased expression of TUBA1B mRNA Lovastatin results in decreased expression of TUBA1B mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 7:130,090,663...130,093,644
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
ISO |
Lovastatin results in decreased expression of TUBB5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases expression |
ISO |
Lovastatin results in decreased expression of TUFM mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
U2af2 |
U2 small nuclear RNA auxiliary factor 2 |
increases expression |
ISO |
Lovastatin results in increased expression of U2AF2 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 1:68,760,911...68,779,730
Ensembl chr 1:68,760,924...68,778,492
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
[Dietary Fats co-treated with Lovastatin] affects the expression of UCP2 mRNA |
CTD |
PMID:29852127 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 |
decreases expression |
ISO |
Lovastatin results in decreased expression of USP5 mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 4:157,619,663...157,634,681
Ensembl chr 4:157,619,643...157,634,711
|
|
G |
Vcp |
valosin-containing protein |
decreases expression increases expression |
ISO |
Lovastatin results in decreased expression of VCP mRNA Lovastatin results in increased expression of VCP mRNA |
CTD |
PMID:20493250 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
multiple interactions increases expression |
ISO |
Lovastatin inhibits the reaction [Doxorubicin results in increased expression of WEE1 mRNA] Lovastatin results in increased expression of WEE1 mRNA |
CTD |
PMID:22712078 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
EXP |
Lovastatin results in increased expression of XIAP mRNA |
CTD |
PMID:26739623 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Xpa |
XPA, DNA damage recognition and repair factor |
increases expression |
EXP |
Lovastatin results in increased expression of XPA mRNA |
CTD |
PMID:26739623 |
|
NCBI chr 5:60,431,673...60,475,726
Ensembl chr 5:60,431,673...60,475,726
|
|
G |
Ywhae |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon |
increases expression |
ISO |
Lovastatin results in increased expression of YWHAE mRNA |
CTD |
PMID:20493250 |
|
NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression decreases expression |
EXP ISO |
[[colestimide co-treated with Pravastatin] results in increased expression of ABCA1 protein] which results in decreased abundance of Cholesterol; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 mRNA; [colestimide co-treated with Pravastatin] affects the expression of ABCA1 protein cotreatment with pravastatin and colestimide increases expression of abca1 mRNA and protein in rat liver; and decreases expression of abca1 mRNA and protein in rat small intestine Pravastatin results in decreased expression of ABCA1 |
CTD RGD |
PMID:17526932 PMID:19461118 PMID:17526932 |
RGD:2308820 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions affects import |
ISO |
Pravastatin inhibits the reaction [ABCB11 protein affects the import of Taurocholic Acid] ABCB11 protein affects the import of Pravastatin |
CTD |
PMID:15901796 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport |
ISO |
ABCB1 protein results in increased transport of Pravastatin; ABCB1 protein results in increased transport of Pravastatin analog |
CTD |
PMID:15616150 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCB4 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export increases expression multiple interactions affects transport |
ISO EXP |
ABCC2 protein affects the export of Pravastatin Pravastatin results in increased expression of ABCC2 protein ABCC2 protein binds to and results in increased uptake of Pravastatin analog; Pravastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Pravastatin promotes the reaction [ABCC2 protein results in increased export of 5(6)-carboxy-2',7'-dichlorofluorescein] ABCC2 protein affects the transport of Pravastatin |
CTD |
PMID:15901800 PMID:15955871 PMID:23562342 PMID:24909372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCC3 protein |
CTD |
PMID:24909372 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Pravastatin |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ABCD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects export increases activity |
ISO |
ABCG2 protein affects the export of Pravastatin Pravastatin results in increased activity of ABCG2 protein |
CTD |
PMID:15901800 PMID:27475308 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
Pravastatin results in increased expression of ABCG8 mRNA |
CTD |
PMID:15242490 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACAA1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACAA2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACAT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein] |
CTD |
PMID:29682576 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein] |
CTD |
PMID:29682576 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ACOT1 mRNA Pravastatin results in decreased expression of ACOT1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acot12 |
acyl-CoA thioesterase 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOT12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:22,986,867...23,027,538
Ensembl chr 2:22,986,626...23,027,536
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
affects expression |
ISO |
Pravastatin affects the expression of ACOT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acot3 |
acyl-CoA thioesterase 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACOT3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,682,518...103,688,735
Ensembl chr 6:103,682,596...103,688,427 Ensembl chr 6:103,682,596...103,688,427
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACOT4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ACOX1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsf2 |
acyl-CoA synthetase family member 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ACSF2 mRNA Pravastatin results in decreased expression of ACSF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:79,504,510...79,546,714
Ensembl chr10:79,504,511...79,546,673
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of ACSL1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ACTA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Adamdec1 |
ADAM-like, decysin 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of ADAMDEC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:42,900,629...42,921,684
Ensembl chr15:42,900,636...42,921,712
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ADH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ADH7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Agt |
angiotensinogen |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AGT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AIF1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of AKR1C18 mRNA Pravastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased activity of and results in increased phosphorylation of AKT1 protein] [Pravastatin co-treated with olmesartan] results in increased phosphorylation of AKT1 protein; [resveratrol co-treated with Pravastatin] results in increased phosphorylation of AKT1 protein Pravastatin results in increased phosphorylation of AKT1 protein |
CTD |
PMID:17170375 PMID:17188708 PMID:18483861 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:16763553 PMID:27225895 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions decreases expression |
ISO |
Cholesterol, Dietary inhibits the reaction [Pravastatin results in decreased expression of ALDH1A2 mRNA] |
CTD |
PMID:16763553 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
affects expression |
EXP ISO |
Pravastatin affects the expression of ALDH1A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:119,982,272...120,017,416
Ensembl chr 1:119,982,277...120,017,436
|
|
G |
Aldoart2 |
aldolase 1 A retrogene 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ALDOART2 mRNA Pravastatin results in decreased expression of ALDOART2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:72,939,821...72,941,511
Ensembl chr 6:72,939,788...72,941,709
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of AMPD3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Ank2 |
ankyrin 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ANK2 mRNA Pravastatin results in decreased expression of ANK2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:215,378,028...215,954,015
Ensembl chr 2:215,379,680...215,862,923
|
|
G |
Anks6 |
ankyrin repeat and sterile alpha motif domain containing 6 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ANKS6 mRNA Pravastatin results in decreased expression of ANKS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:61,309,183...61,350,596
Ensembl chr 5:61,309,183...61,350,596
|
|
G |
Apoa1 |
apolipoprotein A1 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of APOA1 mRNA Pravastatin results in decreased expression of APOA1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
Pravastatin results in increased expression of APP |
CTD |
PMID:19461118 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arg2 |
arginase 2 |
increases expression |
ISO |
Pravastatin results in increased expression of ARG2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of ARHGAP11A mRNA Pravastatin affects the expression of ARHGAP11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ARRDC3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Atp4a |
ATPase H+/K+ transporting subunit alpha |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of ATP4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of ATP6V0D2 mRNA Pravastatin results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Axin2 |
axin 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of AXIN2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of BARD1 mRNA Pravastatin affects the expression of BARD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein |
CTD |
PMID:26875785 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein |
CTD |
PMID:26875785 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713
|
|
G |
Bmal2 |
basic helix-loop-helix ARNT like 2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of BMAL2 mRNA Pravastatin results in increased expression of BMAL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:179,699,432...179,747,710
Ensembl chr 4:179,699,502...179,746,949
|
|
G |
Bmper |
BMP-binding endothelial regulator |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of BMPER mRNA Pravastatin results in increased expression of BMPER mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of BUB1B mRNA Pravastatin results in decreased expression of BUB1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C1qb |
complement C1q B chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of C1QB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C1qc |
complement C1q C chain |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of C1QC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:149,127,412...149,130,757
Ensembl chr 5:149,127,415...149,131,017
|
|
G |
C5ar1 |
complement C5a receptor 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage |
ISO EXP |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein; Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein] Pravastatin results in increased cleavage of CASP3 protein Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP3 protein]; Pravastatin inhibits the reaction [Cisplatin results in increased expression of CASP3 protein] |
CTD |
PMID:18483861 PMID:20368269 PMID:26875785 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CASP9 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity |
ISO |
Pravastatin results in increased activity of CAT protein |
CTD |
PMID:17479860 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CCL12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of CCL2 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of CCL2 protein] |
CTD |
PMID:18323514 PMID:20884875 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CCL6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Cd209d |
CD209d molecule |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CD209 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:1,891,109...1,897,559
Ensembl chr12:1,891,113...1,901,171
|
|
G |
Cd28 |
Cd28 molecule |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CD28 mRNA Pravastatin affects the expression of CD28 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd40 |
CD40 molecule |
affects expression |
EXP ISO |
Pravastatin affects the expression of CD40 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd7 |
Cd7 molecule |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CD7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:106,304,046...106,306,963
Ensembl chr10:106,304,056...106,306,967
|
|
G |
Cdc27 |
cell division cycle 27 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CDC27 mRNA Pravastatin results in increased expression of CDC27 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of CDC6 mRNA Pravastatin affects the expression of CDC6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdca7l |
cell division cycle associated 7 like |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of CDCA7L mRNA Pravastatin results in decreased expression of CDCA7L mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888
|
|
G |
Cdhr5 |
cadherin-related family member 5 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CDHR5 mRNA Pravastatin results in increased expression of CDHR5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:196,373,110...196,381,609
Ensembl chr 1:196,373,112...196,381,543
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Benzo(a)pyrene results in decreased degradation of CDKN1A protein]; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] |
CTD |
PMID:15625077 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cds1 |
CDP-diacylglycerol synthase 1 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CDS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
Pravastatin results in increased expression of CEBPD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cers6 |
ceramide synthase 6 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CERS6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:53,630,637...53,879,692
Ensembl chr 3:53,630,959...53,876,848
|
|
G |
Cesl1 |
carboxylesterase-like 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CESL1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:22,670,709...23,006,329
Ensembl chr19:22,670,712...22,712,608
|
|
G |
Cfap96 |
cilia and flagella associated protein 96 |
increases expression |
EXP |
Pravastatin results in increased expression of CFAP96 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625
|
|
G |
Cip2a |
cellular inhibitor of PP2A |
decreases expression |
EXP |
Pravastatin results in decreased expression of CIP2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CITED1 mRNA Pravastatin results in increased expression of CITED1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of CLCN6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:158,434,299...158,465,174
Ensembl chr 5:158,434,299...158,465,059
|
|
G |
Clec4f |
C-type lectin domain family 4, member F |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CLEC4F mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:116,129,023...116,138,744
Ensembl chr 4:116,129,023...116,138,775
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CLSTN3 mRNA Pravastatin affects the expression of CLSTN3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cnn1 |
calponin 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of CNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CPT1B mRNA Pravastatin affects the expression of CPT1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Pravastatin results in decreased expression of CPT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crat |
carnitine O-acetyltransferase |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of CRAT mRNA Pravastatin affects the expression of CRAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of CREB3L3 mRNA Pravastatin affects the expression of CREB3L3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crp |
C-reactive protein |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of CRP mRNA Pravastatin results in increased expression of CRP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSAD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSF1R mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csmd1 |
CUB and Sushi multiple domains 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CSMD1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:72,218,189...73,818,380
Ensembl chr16:72,218,503...73,817,614
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization multiple interactions |
EXP |
Pravastatin affects the localization of CTNNB1 protein [resveratrol co-treated with Pravastatin] affects the localization of CTNNB1 protein |
CTD |
PMID:17188708 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CXCL2 mRNA Pravastatin results in increased expression of CXCL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYBA protein |
CTD |
PMID:17170375 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in increased expression of CYCS protein] |
CTD |
PMID:18483861 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of CYP1B1 mRNA Pravastatin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b21 |
cytochrome P450, family 2, subfamily b, polypeptide 21 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2B21 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:81,886,097...81,915,066
Ensembl chr 1:81,886,098...81,915,066
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
affects expression |
ISO |
Pravastatin affects the expression of CYP2B10 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2d3 |
cytochrome P450, family 2, subfamily d, polypeptide 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2D3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP2J4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
affects expression |
EXP |
Pravastatin affects the expression of CYP4A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
decreases expression |
EXP |
Pravastatin results in decreased expression of CYP4A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Decr1 |
2,4-dienoyl-CoA reductase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DECR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:29,411,172...29,439,054
Ensembl chr 5:29,411,172...29,439,018
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of DEPDC1B mRNA Pravastatin affects the expression of DEPDC1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Derl3 |
derlin 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of DERL3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of DIO3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dlgap1 |
DLG associated protein 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of DLGAP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:109,857,500...110,726,817
Ensembl chr 9:110,167,448...110,726,817
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
affects farnesylation |
ISO |
Pravastatin affects the farnesylation of DNAJA1 protein |
CTD |
PMID:20884875 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnase2b |
deoxyribonuclease 2 beta |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of DNASE2B mRNA Pravastatin results in decreased expression of DNASE2B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:235,470,915...235,515,211
Ensembl chr 2:235,470,919...235,486,295
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of DPYSL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
decreases expression affects expression |
EXP ISO |
Pravastatin results in decreased expression of DTL mRNA Pravastatin affects the expression of DTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ECH1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EDN1 protein Pravastatin results in decreased expression of EDN1 mRNA; Pravastatin results in decreased expression of EDN1 protein |
CTD |
PMID:12105140 PMID:19812503 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Efhb |
EF hand domain family, member B |
increases expression |
ISO EXP |
Pravastatin results in increased expression of EFHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of EHHADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Enpp5 |
ectonucleotide pyrophosphatase/phosphodiesterase family member 5 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of ENPP5 mRNA Pravastatin results in decreased expression of ENPP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:16,910,187...16,917,633
Ensembl chr 9:16,910,831...16,917,480
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of ENTPD2 mRNA Pravastatin results in increased expression of ENTPD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EPHX2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Ephx4 |
epoxide hydrolase 4 |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of EPHX4 mRNA Pravastatin affects the expression of EPHX4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:2,343,376...2,372,680
Ensembl chr14:2,340,248...2,373,022
|
|
G |
Evi2a |
ecotropic viral integration site 2A |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of EVI2A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of F13A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of FABP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fabp2 |
fatty acid binding protein 2 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of FABP2 mRNA Pravastatin results in decreased expression of FABP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
|
|
G |
Fabp5 |
fatty acid binding protein 5 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of FABP5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:91,765,056...91,768,716
Ensembl chr 2:91,765,056...91,853,773
|
|
G |
Far1 |
fatty acyl CoA reductase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FAR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:167,644,622...167,705,868
Ensembl chr 1:167,644,677...167,705,730
|
|
G |
Fbn1 |
fibrillin 1 |
increases expression |
ISO |
Pravastatin results in increased expression of FBN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbp2 |
fructose-bisphosphatase 2 |
affects expression |
EXP |
Pravastatin affects the expression of FBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:2,236,088...2,253,702
Ensembl chr17:2,236,336...2,253,698
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
affects activity |
ISO |
Pravastatin affects the activity of FDFT1 protein |
CTD |
PMID:8517861 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fgd2 |
FYVE, RhoGEF and PH domain containing 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of FGD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:7,424,795...7,441,603
Ensembl chr20:7,424,790...7,441,603
|
|
G |
Fgf13 |
fibroblast growth factor 13 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of FGF13 mRNA Pravastatin results in increased expression of FGF13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:137,276,498...137,800,056
Ensembl chr X:137,276,511...137,800,391
|
|
G |
Flacc1 |
flagellum associated containing coiled-coil domains 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of FLACC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Folr2 |
folate receptor beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of FOLR2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:156,200,044...156,218,380
Ensembl chr 1:156,200,060...156,205,724
|
|
G |
Foxo1 |
forkhead box O1 |
decreases phosphorylation |
ISO |
Pravastatin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gck |
glucokinase |
decreases expression |
EXP |
Pravastatin results in decreased expression of GCK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of GCLC mRNA Pravastatin results in decreased expression of GCLC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of GCNT2 mRNA Pravastatin results in decreased expression of GCNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased activity of GLB1 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased activity of GLB1 protein] |
CTD |
PMID:20884875 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gldc |
glycine decarboxylase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GLDC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097
|
|
G |
Gls2 |
glutaminase 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of GLS2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:617,252...633,424
Ensembl chr 7:617,288...633,426
|
|
G |
Gpr85 |
G protein-coupled receptor 85 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of GPR85 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:42,102,941...42,109,566
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of GSTK1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Hadh |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HADH mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353
|
|
G |
Hadha |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
|
|
G |
Hadhb |
hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of HADHB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:26,153,572...26,187,668
Ensembl chr 6:26,153,578...26,184,869
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
EXP ISO |
Pravastatin results in increased expression of HAMP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hax1 |
HCLS1 associated protein X-1 |
multiple interactions |
EXP |
Pravastatin inhibits the reaction [Carboplatin results in decreased expression of HAX1 protein] |
CTD |
PMID:18483861 |
|
NCBI chr 2:175,434,242...175,437,926
Ensembl chr 2:175,434,238...175,437,714
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance increases expression decreases activity affects expression |
ISO EXP |
HMGCR gene SNP results in decreased susceptibility to Pravastatin Pravastatin results in increased expression of HMGCR mRNA Pravastatin results in decreased activity of HMGCR protein Pravastatin affects the expression of HMGCR mRNA |
CTD |
PMID:8517861 PMID:8593127 PMID:15199031 PMID:27225895 PMID:29969672 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Pravastatin results in increased expression of HMGCS1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
EXP ISO |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with pirinixic acid] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin results in increased expression of HMOX1 protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:20368269 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hopx |
HOP homeobox |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HOPX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:31,055,912...31,082,909
Ensembl chr14:31,075,148...31,082,909
|
|
G |
Hrg |
histidine-rich glycoprotein |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of HRG mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:78,054,488...78,069,402
Ensembl chr11:78,054,498...78,069,389
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of HSD17B7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:82,170,079...82,190,018
Ensembl chr13:82,173,179...82,190,017
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of HSDL2 mRNA Pravastatin results in increased expression of HSDL2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IFNB1 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IFNB1 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of IL1B mRNA Pravastatin results in increased expression of IL1B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of IL6 mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased secretion of IL6 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased secretion of IL6 protein] Pravastatin results in decreased expression of IL6 protein |
CTD |
PMID:17729120 PMID:18323514 PMID:19330073 PMID:20884875 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases response to substance |
EXP ISO |
[INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in decreased expression of ACE2 protein]; [INS1 protein co-treated with Pravastatin] inhibits the reaction [Streptozocin results in increased expression of ACE protein] [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein |
CTD |
PMID:26875785 PMID:29682576 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Palmitic Acid results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
EXP ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgb1 |
integrin subunit beta 1 |
multiple interactions |
EXP ISO |
geranylgeraniol inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Mevalonic Acid inhibits the reaction [Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein]]; Pravastatin results in increased expression of [ITGA2 protein binds to ITGB1 protein] |
CTD |
PMID:12500026 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb6 |
integrin subunit beta 6 |
affects expression |
ISO |
Pravastatin affects the expression of ITGB6 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Kcns3 |
potassium voltage-gated channel, modifier subfamily S, member 3 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of KCNS3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:33,808,314...33,865,018
Ensembl chr 6:33,808,216...33,865,125
|
|
G |
Kctd12 |
potassium channel tetramerization domain containing 12 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KCTD12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:79,800,078...79,806,017
Ensembl chr15:79,801,191...79,806,282
|
|
G |
Kif20a |
kinesin family member 20A |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF20A mRNA Pravastatin results in decreased expression of KIF20A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif20b |
kinesin family member 20B |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF20B mRNA Pravastatin results in decreased expression of KIF20B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787
|
|
G |
Kif23 |
kinesin family member 23 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of KIF23 mRNA Pravastatin results in decreased expression of KIF23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kitlg |
KIT ligand |
increases expression affects expression |
EXP ISO |
Pravastatin results in increased expression of KITLG mRNA Pravastatin affects the expression of KITL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Klb |
klotho beta |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of KLB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:42,899,050...42,950,788
Ensembl chr14:42,899,510...42,950,799
|
|
G |
Krt23 |
keratin 23 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of KRT23 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:84,434,445...84,450,773
Ensembl chr10:84,434,380...84,450,983
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases activity increases response to substance multiple interactions |
ISO |
Pravastatin results in increased activity of LDLR protein [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased susceptibility to INS1 protein; LDLR gene mutant form results in increased susceptibility to Pravastatin [LDLR gene mutant form results in increased susceptibility to Pravastatin] inhibits the reaction [Glucose results in increased secretion of INS1 protein]; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BAX protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which affects the expression of BCL2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of INS1 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein; [LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in increased cleavage of CASP3 protein |
CTD |
PMID:8593127 PMID:26875785 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of CCL2 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of IL6 mRNA]; Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lgals4 |
galectin 4 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of LGALS4 mRNA Pravastatin results in decreased expression of LGALS4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:84,124,766...84,132,481
Ensembl chr 1:84,124,764...84,132,481
|
|
G |
Lgi2 |
leucine-rich repeat LGI family, member 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LGI2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:58,415,965...58,443,450
Ensembl chr14:58,415,965...58,443,407
|
|
G |
Lmna |
lamin A/C |
increases expression |
ISO |
Pravastatin results in increased expression of LMNA protein |
CTD |
PMID:20884875 |
|
NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of LPL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrmda |
leucine rich melanocyte differentiation associated |
decreases expression |
ISO |
Pravastatin results in decreased expression of LRMDA mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:1,223,098...2,284,764
Ensembl chr15:1,225,710...2,284,749
|
|
G |
Lss |
lanosterol synthase |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LSS mRNA |
CTD |
PMID:27225895 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Ltbp2 |
latent transforming growth factor beta binding protein 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of LTBP2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208
|
|
G |
Ly86 |
lymphocyte antigen 86 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of LY86 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260
|
|
G |
Mapt |
microtubule-associated protein tau |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MAPT Pravastatin results in decreased expression of MAPT mRNA |
CTD |
PMID:19461118 PMID:27225895 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mastl |
microtubule associated serine/threonine kinase-like |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of MASTL mRNA Pravastatin results in decreased expression of MASTL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:85,250,512...85,287,479
Ensembl chr17:85,251,997...85,287,353
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases phosphorylation increases expression multiple interactions |
ISO EXP |
Pravastatin results in increased phosphorylation of MDM2 protein Pravastatin results in increased expression of MDM2 protein [Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Sirolimus inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein]; U 0126 inhibits the reaction [Pravastatin results in increased phosphorylation of MDM2 protein] |
CTD |
PMID:15625077 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Meiob |
meiosis specific with OB-fold |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of MEIOB mRNA Pravastatin results in increased expression of MEIOB mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:13,833,170...13,865,684
Ensembl chr10:13,833,750...13,865,046
|
|
G |
Mgll |
monoglyceride lipase |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of MGLL mRNA Pravastatin affects the expression of MGLL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Miox |
myo-inositol oxygenase |
decreases expression |
ISO |
Pravastatin results in decreased expression of MIOX mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:120,405,031...120,407,529
Ensembl chr 7:120,405,031...120,407,537
|
|
G |
Mis18a |
MIS18 kinetochore protein A |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of MIS18A mRNA Pravastatin results in decreased expression of MIS18A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr11:29,968,030...29,981,058
Ensembl chr11:29,967,701...29,981,062
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of MLYCD mRNA Pravastatin affects the expression of MLYCD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Mme |
membrane metallo-endopeptidase |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of MME mRNA Pravastatin results in decreased expression of MME mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
decreases expression |
EXP |
Pravastatin results in decreased expression of MMP14 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity decreases expression |
EXP |
Pravastatin results in decreased activity of MMP2 protein Pravastatin results in decreased expression of MMP2 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
affects response to substance |
ISO |
MMP3 promoter polymorphism affects the susceptibility to Pravastatin |
CTD |
PMID:8662692 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity decreases expression |
EXP |
Pravastatin results in decreased activity of MMP9 protein Pravastatin results in decreased expression of MMP9 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mss51 |
MSS51 mitochondrial translational activator |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of MSS51 mRNA Pravastatin results in increased expression of MSS51 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr15:3,805,240...3,819,385
Ensembl chr15:3,807,516...3,819,385
|
|
G |
Mstn |
myostatin |
increases expression |
ISO |
Pravastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Pravastatin results in increased phosphorylation of MTOR protein |
CTD |
PMID:15625077 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
EXP ISO |
Pravastatin results in increased expression of MVD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Nfe2 |
nuclear factor, erythroid 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of NFE2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:134,382,758...134,395,364
Ensembl chr 7:134,382,761...134,390,108
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of NNMT mRNA Pravastatin results in increased expression of NNMT protein Pravastatin results in decreased expression of NNMT mRNA |
CTD |
PMID:27225895 PMID:33073877 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA]; Pravastatin inhibits the reaction [Poly I-C results in increased expression of NOS2 mRNA] |
CTD |
PMID:18323514 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases phosphorylation |
EXP |
[Resveratrol co-treated with Pravastatin] results in increased phosphorylation of NOS3 protein; Pravastatin promotes the reaction [NOS3 protein binds to NOS3 protein]; Pravastatin promotes the reaction [olmesartan results in increased activity of and results in increased phosphorylation of NOS3 protein]; Pravastatin results in increased activity of and results in increased phosphorylation of NOS3 protein Pravastatin results in increased phosphorylation of NOS3 protein |
CTD |
PMID:17170375 PMID:17188708 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of NR0B2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
increases expression |
EXP ISO |
Pravastatin results in increased expression of NSDHL mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
increases expression |
ISO |
Pravastatin results in increased expression of OLR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Orc1 |
origin recognition complex, subunit 1 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of ORC1 mRNA Pravastatin results in decreased expression of ORC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375
|
|
G |
P2ry10b |
P2Y receptor family member 10B |
affects expression |
ISO EXP |
Pravastatin affects the expression of P2RY10B mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:72,255,526...72,281,013
Ensembl chr X:72,238,713...72,281,012
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PCDHB4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PCSK9 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pctp |
phosphatidylcholine transfer protein |
decreases expression |
ISO |
Pravastatin results in decreased expression of PCTP mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:74,808,887...74,856,260
Ensembl chr10:74,808,887...74,849,867
|
|
G |
Pde4a |
phosphodiesterase 4A |
decreases expression increases expression |
ISO EXP |
Pravastatin results in decreased expression of PDE4A mRNA Pravastatin results in increased expression of PDE4A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of PDK4 mRNA Pravastatin results in increased expression of PDK4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pemt |
phosphatidylethanolamine N-methyltransferase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PEMT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013
|
|
G |
Pex11a |
peroxisomal biogenesis factor 11 alpha |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PEX11A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172
|
|
G |
Pf4 |
platelet factor 4 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PF4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pla2r1 |
phospholipase A2 receptor 1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PLA2R1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:44,883,943...45,013,793
Ensembl chr 3:44,883,943...45,013,660
|
|
G |
Plppr1 |
phospholipid phosphatase related 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of PLPPR1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:63,437,457...63,725,286
Ensembl chr 5:63,437,816...63,763,835
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases expression |
EXP ISO |
Pravastatin results in increased expression of PMVK mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
|
|
G |
Pnpla7 |
patatin-like phospholipase domain containing 7 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PNPLA7 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:7,782,572...7,861,504
Ensembl chr 3:7,782,572...7,861,497
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of POLE2 mRNA Pravastatin results in decreased expression of POLE2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions affects localization |
ISO EXP |
Pravastatin results in increased expression of PPARA protein Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] Pravastatin affects the localization of PPARA protein [[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Pravastatin affects the localization of PPARA protein]; Pravastatin promotes the reaction [PPARA protein binds to HMOX1 promoter] |
CTD |
PMID:18812576 PMID:20368269 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [[troglitazone binds to and results in increased activity of PPARG protein] which results in increased abundance of Cholesterol] |
CTD |
PMID:12044893 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppm1j |
protein phosphatase, Mg2+/Mn2+ dependent, 1J |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of PPM1J mRNA Pravastatin results in increased expression of PPM1J mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:192,278,597...192,283,883
Ensembl chr 2:192,278,517...192,283,882
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases activity |
ISO |
Pravastatin results in increased activity of PRKAA1 protein |
CTD |
PMID:33073877 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prnd |
prion like protein doppel |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of PRND mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:119,213,462...119,218,742
Ensembl chr 3:119,213,429...119,218,745
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
Pravastatin results in increased expression of PTGS2 protein |
CTD |
PMID:20368269 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptprn |
protein tyrosine phosphatase, receptor type, N |
increases expression affects expression |
ISO EXP |
Pravastatin results in increased expression of PTPRN mRNA Pravastatin affects the expression of PTPRN mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:76,741,010...76,756,704
Ensembl chr 9:76,741,016...76,756,190
|
|
G |
Rdh11 |
retinol dehydrogenase 11 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of RDH11 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:97,979,377...97,995,252
Ensembl chr 6:97,979,378...97,995,252
|
|
G |
Reep1 |
receptor accessory protein 1 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of REEP1 mRNA Pravastatin results in increased expression of REEP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:103,746,004...103,862,347
Ensembl chr 4:103,745,633...103,862,338
|
|
G |
Retsat |
retinol saturase |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of RETSAT mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:104,653,306...104,662,069
Ensembl chr 4:104,653,155...104,668,310
|
|
G |
Rgs16 |
regulator of G-protein signaling 16 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of RGS16 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:65,887,668...65,892,862
Ensembl chr13:65,887,530...65,892,857
|
|
G |
Rnf186 |
ring finger protein 186 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of RNF186 mRNA Pravastatin affects the expression of RNF186 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:151,210,492...151,211,716
Ensembl chr 5:151,210,492...151,211,716
|
|
G |
Rragd |
Ras-related GTP binding D |
decreases expression |
ISO |
Pravastatin results in decreased expression of RRAGD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:47,373,902...47,409,369
Ensembl chr 5:47,373,463...47,409,356
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
EXP |
[[Pravastatin co-treated with pirinixic acid] co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA; [Pravastatin co-treated with [RXRA protein co-treated with PPARA protein]] results in increased expression of HMOX1 mRNA |
CTD |
PMID:20368269 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of S100A4 mRNA Pravastatin results in increased expression of S100A4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
S100g |
S100 calcium binding protein G |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of S100G mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:31,705,853...31,708,422
Ensembl chr X:31,705,866...31,708,433
|
|
G |
Sat2 |
spermidine/spermine N1-acetyltransferase family member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SAT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:54,340,756...54,343,507
Ensembl chr10:54,340,372...54,343,224
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
EXP |
Pravastatin results in increased expression of SCD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scd2 |
stearoyl-Coenzyme A desaturase 2 |
increases expression |
ISO |
Pravastatin results in increased expression of SCD2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
|
|
G |
Selp |
selectin P |
decreases expression |
ISO |
Pravastatin results in decreased expression of SELP protein |
CTD |
PMID:11189483 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpinb1a |
serpin family B member 1A |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SERPINB1A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,590,677...31,599,102
|
|
G |
Sfrp1 |
secreted frizzled-related protein 1 |
increases expression |
ISO |
Pravastatin results in increased expression of SFRP1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:68,575,763...68,614,180
Ensembl chr16:68,575,763...68,614,286
|
|
G |
Shisa4 |
shisa family member 4 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of SHISA4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:46,799,735...46,803,816
Ensembl chr13:46,799,772...46,803,998
|
|
G |
Sirt1 |
sirtuin 1 |
increases phosphorylation |
ISO |
Pravastatin results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:33073877 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc13a3 |
solute carrier family 13 member 3 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SLC13A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:154,141,878...154,204,604
Ensembl chr 3:154,141,872...154,204,606
|
|
G |
Slc15a3 |
solute carrier family 15 member 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC15A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:207,492,365...207,507,158
Ensembl chr 1:207,492,365...207,507,157
|
|
G |
Slc16a5 |
solute carrier family 16 member 5 |
decreases expression affects expression |
ISO EXP |
Pravastatin results in decreased expression of SLC16A5 mRNA Pravastatin affects the expression of SLC16A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:100,707,434...100,721,338
Ensembl chr10:100,707,434...100,721,338
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc17a3 |
solute carrier family 17 member 3 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC17A3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr17:41,270,804...41,300,132
Ensembl chr17:41,270,812...41,295,256
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of SLC22A5 mRNA Pravastatin results in decreased expression of SLC22A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc23a1 |
solute carrier family 23 member 1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC23A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:27,214,940...27,230,564
Ensembl chr18:27,216,281...27,230,697
|
|
G |
Slc25a20 |
solute carrier family 25 member 20 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SLC25A20 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:109,365,056...109,386,512
Ensembl chr 8:109,365,002...109,386,512
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
affects expression |
EXP |
Pravastatin affects the expression of SLC25A34 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:153,932,081...153,936,854
|
|
G |
Slc25a42 |
solute carrier family 25, member 42 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC25A42 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr16:19,213,914...19,251,990
Ensembl chr16:19,213,950...19,237,025
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SLC27A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC2A4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc34a2 |
solute carrier family 34 member 2 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of SLC34A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:57,910,931...57,930,236
Ensembl chr14:57,910,480...57,930,436
|
|
G |
Slc9b2 |
solute carrier family 9 member B2 |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of SLC9B2 mRNA Pravastatin results in increased expression of SLC9B2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:223,726,982...223,761,234
Ensembl chr 2:223,736,354...223,761,225
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
affects transport decreases expression |
ISO EXP |
SLCO1A4 protein affects the transport of Pravastatin Pravastatin results in decreased expression of SLCO1A4 protein |
CTD |
PMID:19833843 PMID:24909372 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1a5 |
solute carrier organic anion transporter family, member 1A5 |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of SLCO1A5 mRNA Pravastatin results in decreased expression of SLCO1A5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:175,172,390...175,254,598
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Pravastatin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] |
CTD |
PMID:21430235 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Slco4a1 |
solute carrier organic anion transporter family, member 4a1 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305
|
|
G |
Smim3 |
small integral membrane protein 3 |
increases expression |
ISO |
Pravastatin results in increased expression of SMIM3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:53,930,019...53,982,339
Ensembl chr18:53,930,020...53,957,416
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of SNAP25 protein |
CTD |
PMID:26875785 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
Pravastatin results in increased expression of SOCS3 protein |
CTD |
PMID:19330073 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Spag5 |
sperm associated antigen 5 |
affects expression decreases expression |
ISO EXP |
Pravastatin affects the expression of SPAG5 mRNA Pravastatin results in decreased expression of SPAG5 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745
|
|
G |
Spic |
Spi-C transcription factor |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of SPIC mRNA Pravastatin results in increased expression of SPIC mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:23,069,815...23,077,517
Ensembl chr 7:23,069,821...23,077,548
|
|
G |
Srd5a2 |
steroid 5 alpha-reductase 2 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SRD5A2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:21,426,225...21,465,727
Ensembl chr 6:21,426,215...21,462,112
|
|
G |
St8sia3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of ST8SIA3 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839
|
|
G |
Stard4 |
StAR-related lipid transfer domain containing 4 |
increases expression |
ISO EXP |
Pravastatin results in increased expression of STARD4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr18:24,814,683...24,830,024
Ensembl chr18:24,817,107...24,830,024
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Pravastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:18323514 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
Pravastatin results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:19330073 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stx1a |
syntaxin 1A |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of STX1A protein |
CTD |
PMID:26875785 |
|
NCBI chr12:21,641,971...21,670,022
Ensembl chr12:21,641,969...21,669,930
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
affects expression decreases expression |
EXP ISO |
Pravastatin affects the expression of SULT1C2 mRNA Pravastatin results in decreased expression of SULT1C2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of SULT1E1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tex12 |
testis expressed 12 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of TEX12 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:50,908,161...50,913,202
Ensembl chr 8:50,909,052...50,913,217
|
|
G |
Thbd |
thrombomodulin |
affects expression increases expression |
EXP ISO |
Pravastatin affects the expression of THBD mRNA Pravastatin results in increased expression of THBD mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
EXP |
Pravastatin results in decreased expression of TIMP1 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases expression |
EXP |
Pravastatin results in decreased expression of TIMP2 mRNA |
CTD |
PMID:16935385 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tlcd4 |
TLC domain containing 4 |
decreases expression |
ISO |
Pravastatin results in decreased expression of TLCD4 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 2:209,284,873...209,360,156
Ensembl chr 2:209,289,732...209,341,353
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TM7SF2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tmem139 |
transmembrane protein 139 |
increases expression decreases expression |
EXP ISO |
Pravastatin results in increased expression of TMEM139 mRNA Pravastatin results in decreased expression of TMEM139 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:71,147,072...71,149,151
Ensembl chr 4:71,146,724...71,167,399
|
|
G |
Tmem164 |
transmembrane protein 164 |
decreases expression increases expression |
EXP ISO |
Pravastatin results in decreased expression of TMEM164 mRNA Pravastatin results in increased expression of TMEM164 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640
|
|
G |
Tmem205 |
transmembrane protein 205 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of TMEM205 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 8:20,452,092...20,458,011
Ensembl chr 8:20,452,092...20,457,828
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO |
Pravastatin inhibits the reaction [LEP gene mutant form results in increased expression of TNF mRNA]; Pravastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Pravastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Pravastatin results in increased expression of TNF mRNA |
CTD |
PMID:17729120 PMID:18323514 PMID:27225895 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf18 |
TNF superfamily member 18 |
affects expression |
ISO EXP |
Pravastatin affects the expression of TNFSF18 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:73,833,478...73,907,249
Ensembl chr13:73,831,252...73,843,169
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
ISO |
Pravastatin results in increased expression of TNNT2 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO EXP |
[Pravastatin results in increased phosphorylation of MDM2 protein] which results in increased degradation of TP53 protein; Pravastatin inhibits the reaction [Fluorouracil results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [leptomycin B results in decreased degradation of TP53 protein]; Pravastatin inhibits the reaction [lopinavir-ritonavir drug combination results in increased expression of TP53 protein]; Pravastatin inhibits the reaction [Ritonavir results in increased expression of TP53 protein] Pravastatin inhibits the reaction [Cisplatin results in increased expression of TP53 protein] |
CTD |
PMID:15625077 PMID:20650967 PMID:20884875 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tspan13 |
tetraspanin 13 |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TSPAN13 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 6:52,738,748...52,765,503
Ensembl chr 6:52,738,758...52,765,547
|
|
G |
Ttc41 |
tetratricopeptide repeat domain 41 |
decreases expression |
ISO |
Pravastatin results in decreased expression of TTC41 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:21,124,909...21,188,191
Ensembl chr 7:21,125,105...21,188,189
|
|
G |
Tuba1a |
tubulin, alpha 1A |
increases expression |
EXP ISO |
Pravastatin results in increased expression of TUBA1A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Ugt2b1 |
UDP glucuronosyltransferase 2 family, polypeptide B1 |
decreases expression |
ISO EXP |
Pravastatin results in decreased expression of UGT2B1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr14:21,024,035...21,035,784
Ensembl chr14:21,024,006...21,035,986
|
|
G |
Uroc1 |
urocanate hydratase 1 |
decreases expression |
EXP ISO |
Pravastatin results in decreased expression of UROC1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 4:122,844,933...122,876,584
Ensembl chr 4:122,844,926...122,876,591
|
|
G |
Vamp2 |
vesicle-associated membrane protein 2 |
multiple interactions |
ISO |
[LDLR gene mutant form results in increased susceptibility to Pravastatin] which results in decreased expression of VAMP2 protein |
CTD |
PMID:26875785 |
|
NCBI chr10:53,793,581...53,797,815
Ensembl chr10:53,793,923...53,797,809
|
|
G |
Vnn1 |
vanin 1 |
decreases expression |
ISO |
Pravastatin results in decreased expression of VNN1 mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
increases expression decreases expression |
ISO EXP |
Pravastatin results in increased expression of ZC3H12A mRNA Pravastatin results in decreased expression of ZC3H12A mRNA |
CTD |
PMID:27225895 |
|
NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351
|
|
|
G |
A2m |
alpha-2-macroglobulin |
decreases expression |
EXP |
Simvastatin results in decreased expression of A2M mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of ABCA1; Simvastatin results in decreased expression of ABCA1 mRNA Simvastatin results in increased expression of ABCA1 mRNA Simvastatin results in increased expression of ABCA1 mRNA; Simvastatin results in increased expression of ABCA1 protein |
CTD |
PMID:16282522 PMID:18270459 PMID:19383813 PMID:19461118 PMID:21241519 PMID:22120639 PMID:25055962 More...
|
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Simvastatin results in decreased activity of ABCB11 protein Simvastatin results in decreased expression of ABCB11 mRNA |
CTD |
PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects response to substance decreases activity increases transport |
ISO |
ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; Simvastatin analog inhibits the reaction [ABCB1 protein results in increased transport of calcein AM] ABCB1 polymorphism affects the susceptibility to Simvastatin Simvastatin analog results in decreased activity of ABCB1 protein ABCB1 protein results in increased transport of Simvastatin |
CTD |
PMID:15616150 PMID:16321621 PMID:19802823 PMID:19891551 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of ABCB4 mRNA Simvastatin results in decreased expression of ABCB4 mRNA |
CTD |
PMID:21241519 PMID:27765674 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions decreases activity affects response to substance decreases expression |
EXP ISO |
ABCC2 protein binds to and results in increased uptake of Simvastatin analog; Simvastatin analog inhibits the reaction [ABCC2 protein binds to and results in increased uptake of 5(6)-carboxy-2',7'-dichlorofluorescein]; Simvastatin analog inhibits the reaction [ABCC2 protein results in increased transport of calcein AM] Simvastatin analog results in decreased activity of ABCC2 protein ABCC2 polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased expression of ABCC2 mRNA |
CTD |
PMID:15616150 PMID:22186618 PMID:23562342 PMID:27765674 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases nitrosation |
ISO |
artemisinin inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; parthenolide inhibits the reaction [Simvastatin results in increased nitrosation of ABCC3 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased nitrosation of ABCC3 protein] |
CTD |
PMID:18463201 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ABCG1 mRNA |
CTD |
PMID:19383813 PMID:22120639 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Simvastatin results in increased expression of ABCG5 mRNA |
CTD |
PMID:21241519 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
decreases expression multiple interactions |
EXP |
Simvastatin results in decreased expression of ACAA2 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of ACAA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acacb |
acetyl-CoA carboxylase beta |
increases expression |
EXP |
Simvastatin results in increased expression of ACACB mRNA |
CTD |
PMID:12056585 |
|
NCBI chr12:42,365,800...42,477,651
Ensembl chr12:42,366,548...42,457,655
|
|
G |
Acan |
aggrecan |
multiple interactions increases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ACE2 mRNA |
CTD |
PMID:32808185 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of ACTA2 protein Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA] |
CTD |
PMID:15677772 PMID:15855201 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
increases expression |
EXP |
Simvastatin results in increased expression of ACTB mRNA |
CTD |
PMID:25055962 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actn4 |
actinin alpha 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ACTN4 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO EXP |
Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of ADIPOQ mRNA]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of ADIPOQ protein] carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein]]; Simvastatin inhibits the reaction [Poloxamer results in decreased secretion of ADIPOQ protein] |
CTD |
PMID:17641834 PMID:29071762 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of ADORA2B protein] |
CTD |
PMID:33774062 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ADRB1 mRNA; Simvastatin results in increased expression of ADRB1 protein |
CTD |
PMID:19262002 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of AFP mRNA |
CTD |
PMID:10365819 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein] Simvastatin results in decreased expression of AGER protein |
CTD |
PMID:17038636 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases expression |
ISO EXP |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]] Simvastatin results in decreased expression of AGT mRNA Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA] |
CTD |
PMID:17513949 PMID:18400235 PMID:18475152 PMID:19100119 PMID:19225232 PMID:22306966 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression |
ISO |
Simvastatin results in decreased expression of AGTR1 mRNA |
CTD |
PMID:17513949 PMID:18475152 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
increases expression |
ISO |
Simvastatin results in increased expression of AKR1C1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression multiple interactions decreases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
Simvastatin results in decreased expression of AKT1 mRNA; Simvastatin results in decreased expression of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein; [Simvastatin co-treated with Metformin] results in decreased phosphorylation of AKT1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of AKT1 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased phosphorylation of AKT1 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Nifedipine co-treated with Hydrogen Peroxide] results in increased phosphorylation of AKT1 protein]] Simvastatin inhibits the reaction [Glucose results in decreased expression of AKT1 protein modified form]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of AKT1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of AKT1 protein Simvastatin results in decreased activity of AKT1 protein Simvastatin results in increased phosphorylation of AKT1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein] |
CTD |
PMID:12438947 PMID:17327694 PMID:17335931 PMID:18004065 PMID:18031796 PMID:18047562 PMID:19299917 PMID:20060890 PMID:20464445 PMID:20562903 PMID:20594940 PMID:21059805 PMID:22082490 PMID:22144680 PMID:25412314 PMID:27734117 PMID:33034787 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
increases expression |
ISO |
Simvastatin results in increased expression of ALDH3A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Alk |
ALK receptor tyrosine kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of ALK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
ISO |
Simvastatin results in increased expression of ALOX5AP mRNA |
CTD |
PMID:17183729 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
increases expression |
ISO |
Simvastatin results in increased expression of ALPI mRNA |
CTD |
PMID:14973129 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression affects expression multiple interactions |
ISO |
Simvastatin results in increased expression of ALPL mRNA Simvastatin affects the expression of ALPL mRNA Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA] |
CTD |
PMID:20417880 PMID:28975700 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angpt1 |
angiopoietin 1 |
increases expression |
EXP |
Simvastatin results in increased expression of ANGPT1; Simvastatin results in increased expression of ANGPT1 mRNA; Simvastatin results in increased expression of ANGPT1 protein |
CTD |
PMID:18544044 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of ANGPT2 protein] |
CTD |
PMID:20821229 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ANGPTL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankra2 |
ankyrin repeat family A member 2 |
increases expression |
EXP |
Simvastatin results in increased expression of ANKRA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 2:29,612,867...29,623,748
Ensembl chr 2:29,612,925...29,623,730
|
|
G |
Anpep |
alanyl aminopeptidase, membrane |
increases expression |
ISO |
Simvastatin results in increased expression of ANPEP mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
ISO |
Simvastatin results in increased expression of ANXA1 protein |
CTD |
PMID:14973129 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ANXA3 mRNA Simvastatin results in decreased expression of ANXA3 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of AOC1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Apmap |
adipocyte plasma membrane associated protein |
decreases expression |
EXP |
Simvastatin results in decreased expression of APMAP protein |
CTD |
PMID:20217863 |
|
NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions increases expression decreases expression |
ISO EXP |
MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein] Polystyrenes analog promotes the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Simvastatin promotes the reaction [Polystyrenes analog results in increased expression of APOA1 mRNA] Simvastatin results in increased expression of APOA1 mRNA; Simvastatin results in increased expression of APOA1 protein [Niacin co-treated with Ezetimibe co-treated with Simvastatin] results in increased expression of APOA1 protein; [Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 mRNA]; Homocysteine inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; Niacin promotes the reaction [[Simvastatin co-treated with Ezetimibe] results in increased expression of APOA1 protein]; Simvastatin results in increased expression of and results in increased secretion of APOA1 protein Simvastatin results in decreased expression of APOA1 mRNA; Simvastatin results in decreased expression of APOA1 protein |
CTD |
PMID:8289597 PMID:8461338 PMID:12048122 PMID:12633795 PMID:18270459 PMID:18420099 PMID:18540024 PMID:20152243 PMID:21241519 PMID:25055962 More...
|
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOA2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoa4 |
apolipoprotein A4 |
multiple interactions increases expression decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] Simvastatin results in increased expression of APOA4 protein Polystyrenes analog promotes the reaction [Simvastatin results in decreased expression of APOA4 protein]; Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOA4 protein] Simvastatin results in decreased expression of APOA4 mRNA; Simvastatin results in decreased expression of APOA4 protein |
CTD |
PMID:8289597 PMID:8461338 PMID:18224302 PMID:25055962 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apob |
apolipoprotein B |
multiple interactions affects response to substance decreases expression decreases secretion |
ISO EXP |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Niacin co-treated with Simvastatin] results in decreased expression of APOB protein; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] APOB polymorphism affects the susceptibility to Simvastatin Simvastatin promotes the reaction [Polystyrenes analog results in decreased expression of APOB protein] Simvastatin results in decreased expression of APOB mRNA; Simvastatin results in decreased expression of APOB protein Simvastatin results in decreased secretion of APOB protein |
CTD |
PMID:1627634 PMID:8289597 PMID:8461338 PMID:9512650 PMID:10498134 PMID:11728391 PMID:12633795 PMID:12901521 PMID:15184351 PMID:18471454 PMID:18702965 PMID:20413733 More...
|
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOC1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoc3 |
apolipoprotein C3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOC3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Apoe |
apolipoprotein E |
decreases expression affects response to substance multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of APOE; Simvastatin results in decreased expression of APOE mRNA APOE affects the susceptibility to Simvastatin Polystyrenes analog inhibits the reaction [Simvastatin results in decreased expression of APOE protein] APOE polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased expression of APOE mRNA; Simvastatin results in decreased expression of APOE protein |
CTD |
PMID:8289597 PMID:8461338 PMID:11849659 PMID:11947894 PMID:12901521 PMID:18270459 PMID:19461118 PMID:25055962 More...
|
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Apof |
apolipoprotein F |
decreases expression |
EXP |
Simvastatin results in decreased expression of APOF mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:700,688...702,130
Ensembl chr 7:700,762...701,946
|
|
G |
Apom |
apolipoprotein M |
decreases expression increases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of APOM mRNA Simvastatin results in increased expression of APOM mRNA; Simvastatin results in increased expression of APOM protein T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; T0901317 inhibits the reaction [Simvastatin results in increased expression of APOM protein]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM mRNA]; Ursodeoxycholic Acid inhibits the reaction [Simvastatin results in increased expression of APOM protein] |
CTD |
PMID:21729290 PMID:22160096 |
|
NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases activity |
ISO EXP |
oblimersen inhibits the reaction [Simvastatin results in decreased activity of APP protein alternative form]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein] |
CTD |
PMID:17241114 PMID:28734741 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap29 |
Rho GTPase activating protein 29 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ARHGAP29 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:210,060,036...210,132,572
Ensembl chr 2:210,071,199...210,132,028
|
|
G |
Arhgap4 |
Rho GTPase activating protein 4 |
increases expression |
ISO |
Simvastatin results in increased expression of ARHGAP4 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr X:151,636,071...151,651,528
Ensembl chr X:151,632,454...151,651,128
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of ARHGEF2 mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ASS1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf2 |
activating transcription factor 2 |
increases phosphorylation |
EXP |
Simvastatin results in increased phosphorylation of ATF2 protein |
CTD |
PMID:15488325 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Simvastatin results in increased expression of ATF3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
EXP |
Simvastatin results in increased expression of ATF6 mRNA; Simvastatin results in increased expression of ATF6 protein |
CTD |
PMID:18807172 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Simvastatin results in increased phosphorylation of and results in increased activity of ATM protein |
CTD |
PMID:20499237 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Simvastatin results in increased expression of ATP2A2 mRNA; Simvastatin results in increased expression of ATP2A2 protein |
CTD |
PMID:15916736 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Atp6v1e1 |
ATPase H+ transporting V1 subunit E1 |
increases expression |
ISO |
Simvastatin results in increased expression of ATP6V1E1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:154,022,358...154,044,486
Ensembl chr 4:154,022,358...154,044,584
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Simvastatin results in decreased expression of AURKA mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Axin2 |
axin 2 |
affects expression |
EXP |
Simvastatin affects the expression of AXIN2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases expression |
ISO |
Simvastatin results in decreased expression of AXL mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions decreases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein] |
CTD |
PMID:12438947 PMID:27734117 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases expression |
ISO EXP |
Simvastatin affects the localization of BAX protein Simvastatin results in increased expression of BAX mRNA; Simvastatin results in increased expression of BAX protein |
CTD |
PMID:12557325 PMID:17901590 PMID:20045437 PMID:25300705 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions affects localization increases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BBC3 protein]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 mRNA]; pifithrin inhibits the reaction [Simvastatin results in increased expression of BBC3 protein] Simvastatin affects the localization of BBC3 protein Simvastatin results in increased expression of BBC3 mRNA; Simvastatin results in increased expression of BBC3 protein |
CTD |
PMID:17428261 PMID:20045437 PMID:21199873 PMID:37956312 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of BCL2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in decreased expression of BCL2 mRNA; Simvastatin results in decreased expression of BCL2 protein Simvastatin results in increased expression of BCL2 protein Simvastatin results in increased expression of BCL2 mRNA; Simvastatin results in increased expression of BCL2 protein |
CTD |
PMID:17241114 PMID:17277159 PMID:17901590 PMID:18031796 PMID:18521906 PMID:20369390 PMID:21729534 PMID:25300705 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein] Simvastatin results in decreased expression of BCL2L1 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:20060890 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
Simvastatin results in increased expression of BDNF Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of BDNF mRNA] |
CTD |
PMID:18047562 PMID:20851742 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression increases secretion multiple interactions |
ISO EXP |
Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA Simvastatin results in increased secretion of BGLAP protein [Simvastatin co-treated with Dexamethasone] results in increased expression of BGLAP Simvastatin results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA] Simvastatin results in increased expression of BGLAP; Simvastatin results in increased expression of BGLAP mRNA; Simvastatin results in increased expression of BGLAP protein |
CTD |
PMID:12914771 PMID:14601315 PMID:14973129 PMID:15953866 PMID:17252541 PMID:19216230 PMID:19249597 PMID:19292885 PMID:20381859 PMID:20417880 PMID:20564244 PMID:21431270 PMID:22058016 More...
|
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bhlha15 |
basic helix-loop-helix family, member a15 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of BHLHA15 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr12:10,420,465...10,424,641
Ensembl chr12:10,420,467...10,424,713
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] Simvastatin results in decreased expression of BIRC2 protein |
CTD |
PMID:17277159 PMID:18521906 PMID:19343037 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 mRNA]; Simvastatin inhibits the reaction [Homocysteine results in decreased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] |
CTD |
PMID:17277159 PMID:19343037 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Simvastatin results in decreased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of BIRC5 protein] Simvastatin results in decreased expression of BIRC5 mRNA; Simvastatin results in decreased expression of BIRC5 protein |
CTD |
PMID:17277159 PMID:20464445 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
increases expression |
EXP |
Simvastatin results in increased expression of BMP1 mRNA |
CTD |
PMID:12963647 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases secretion multiple interactions increases expression |
ISO EXP |
Simvastatin results in increased secretion of BMP2 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of BMP2 mRNA] Simvastatin results in increased expression of BMP2; Simvastatin results in increased expression of BMP2 mRNA farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] Simvastatin results in increased expression of BMP2 mRNA; Simvastatin results in increased expression of BMP2 protein |
CTD |
PMID:10814523 PMID:11162604 PMID:12914771 PMID:16470222 PMID:17252541 PMID:18310456 PMID:18628692 PMID:19292885 PMID:19912653 PMID:20024970 PMID:20381859 PMID:20417880 PMID:20687301 More...
|
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
affects expression increases expression increases stability |
ISO |
Simvastatin affects the expression of BMPR2 mRNA Simvastatin results in increased expression of BMPR2 protein Simvastatin results in increased stability of BMPR2 mRNA |
CTD |
PMID:16297860 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Simvastatin results in increased expression of BNIP3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
C5ar1 |
complement C5a receptor 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of C5AR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1C protein] Simvastatin results in decreased expression of CACNA1C mRNA; Simvastatin results in decreased expression of CACNA1C protein |
CTD |
PMID:19791473 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CACNA1H protein] Simvastatin results in decreased expression of CACNA1H mRNA; Simvastatin results in decreased expression of CACNA1H protein |
CTD |
PMID:19791473 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in decreased expression of CALB1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calb2 |
calbindin 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CALB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438
|
|
G |
Cald1 |
caldesmon 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CALD1 mRNA; Simvastatin results in decreased expression of CALD1 protein |
CTD |
PMID:14630613 |
|
NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calml3 |
calmodulin-like 3 |
increases expression |
ISO |
Simvastatin results in increased expression of CALML3 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:66,419,844...66,423,083
Ensembl chr17:66,419,882...66,423,175
|
|
G |
Capn1 |
calpain 1 |
increases expression |
ISO |
Simvastatin results in increased expression of CAPN1 mRNA |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capza1 |
capping actin protein of muscle Z-line subunit alpha 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CAPZA1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 2:192,319,696...192,364,755
Ensembl chr 2:192,319,702...192,364,480
|
|
G |
Capza2 |
capping actin protein of muscle Z-line subunit alpha 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CAPZA2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 4:45,978,142...46,014,032
Ensembl chr 4:45,977,807...46,013,864
|
|
G |
Casp1 |
caspase 1 |
decreases activity multiple interactions |
EXP |
Simvastatin results in decreased activity of CASP1 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of CASP1 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CASP1 protein] |
CTD |
PMID:16054375 PMID:30408459 PMID:35762198 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Simvastatin results in increased cleavage of and results in increased activity of CASP12 protein |
CTD |
PMID:19253821 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression decreases activity |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in decreased expression of CASP3 protein]; Simvastatin inhibits the reaction [APP protein alternative form results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of CASP3 protein modified form]; Simvastatin inhibits the reaction [Homocysteine results in increased activity of CASP3 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein [Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein; [Lipopolysaccharides co-treated with Simvastatin] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; zinc protoporphyrin inhibits the reaction [[Glucose deficiency co-treated with Simvastatin] results in increased cleavage of CASP3 protein] carvacrol inhibits the reaction [Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]]; PD 150606 inhibits the reaction [Simvastatin results in increased activity of CASP3 protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Glucose results in increased cleavage of CASP3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of CASP3 mRNA]; Simvastatin promotes the reaction [Poloxamer results in increased expression of CASP3 protein]; Simvastatin results in decreased expression of and results in decreased activity of CASP3 protein; Simvastatin results in increased cleavage of and results in increased activity of CASP3 protein; Verapamil inhibits the reaction [Simvastatin results in increased activity of CASP3 protein] Simvastatin results in increased expression of CASP3 mRNA; Simvastatin results in increased expression of CASP3 protein Simvastatin results in decreased activity of CASP3 protein |
CTD |
PMID:11868908 PMID:12557325 PMID:12962723 PMID:14527821 PMID:15200425 PMID:15949312 PMID:16054375 PMID:16325779 PMID:16470222 PMID:16698853 PMID:17241114 PMID:17428261 PMID:17928392 PMID:18004065 PMID:18031796 PMID:18521906 PMID:18826357 PMID:19253821 PMID:19343037 PMID:20045437 PMID:20403180 PMID:20427495 PMID:20464445 PMID:20883752 PMID:21651924 PMID:21729534 PMID:21968084 PMID:22022327 PMID:25300705 PMID:26773838 PMID:27734117 PMID:29071762 PMID:35762198 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
Simvastatin results in increased cleavage of and results in increased activity of CASP6 protein |
CTD |
PMID:19253821 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of CASP7 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP7 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP7 protein |
CTD |
PMID:19253821 PMID:20045437 PMID:20427495 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions increases cleavage |
ISO |
Simvastatin results in increased activity of CASP8 protein Acetylcysteine inhibits the reaction [Simvastatin results in increased activity of CASP8 protein] Simvastatin results in increased cleavage of CASP8 protein Simvastatin results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:12962723 PMID:15705602 PMID:20464445 PMID:20883752 PMID:21910007 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage decreases activity increases activity |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased activity of CASP9 protein]; DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of CASP9 protein]; Simvastatin results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:12438947 PMID:12962723 PMID:15705602 PMID:16470222 PMID:19253821 PMID:20045437 PMID:21910007 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression increases activity multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of CAT mRNA Simvastatin results in increased activity of CAT protein carvacrol promotes the reaction [Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein]]; Simvastatin inhibits the reaction [Diazepam results in decreased activity of CAT protein]; Simvastatin inhibits the reaction [Poloxamer results in decreased activity of CAT protein] |
CTD |
PMID:17479860 PMID:20883752 PMID:27111380 PMID:29071762 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [Glucose results in decreased expression of CAV1 mRNA] Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] Simvastatin results in decreased expression of CAV1 protein Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV1 protein] |
CTD |
PMID:16698853 PMID:18224302 PMID:19816600 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Cav2 |
caveolin 2 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [[Semaxinib co-treated with Oxygen deficiency] results in decreased expression of CAV2 protein] |
CTD |
PMID:16698853 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Cbs |
cystathionine beta synthase |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[APOA4 protein co-treated with CBS protein] affects the abundance of Nitrogen Compounds]; Simvastatin promotes the reaction [[APOA4 protein co-treated with CBS protein] affects the expression of CAV1 protein] |
CTD |
PMID:18224302 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression decreases response to substance affects expression |
ISO EXP |
[Simvastatin co-treated with Ramipril] results in decreased expression of CCL2 protein; [Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [AGT protein results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin results in decreased expression of and results in decreased secretion of CCL2 protein Simvastatin results in decreased expression of CCL2 mRNA; Simvastatin results in decreased expression of CCL2 protein Simvastatin results in decreased susceptibility to CCL2 protein Simvastatin affects the expression of CCL2 mRNA |
CTD |
PMID:12117737 PMID:12818400 PMID:15184351 PMID:15781755 PMID:15824212 PMID:15855201 PMID:16321392 PMID:16414398 PMID:16443229 PMID:16781696 PMID:17449418 PMID:18309148 PMID:19225232 PMID:19262002 PMID:21268089 PMID:22305382 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CCL20 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA] Simvastatin results in decreased expression of CCL3 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of CCL5 mRNA Simvastatin results in decreased expression of CCL5 mRNA Simvastatin results in decreased expression of CCL5 protein |
CTD |
PMID:17112859 PMID:17183729 PMID:17449418 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA] Simvastatin results in decreased expression of CCN1 mRNA |
CTD |
PMID:17428261 PMID:20191585 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] Simvastatin results in decreased expression of CCN2 mRNA; Simvastatin results in decreased expression of CCN2 protein |
CTD |
PMID:15200425 PMID:15298857 PMID:15677772 PMID:19080365 PMID:19099753 PMID:19659652 More...
|
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of CCNA2 mRNA geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNA2 protein] |
CTD |
PMID:17428261 PMID:26577051 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein] Simvastatin results in decreased expression of CCND1 mRNA; Simvastatin results in decreased expression of CCND1 protein |
CTD |
PMID:17277159 PMID:17428261 PMID:20878096 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions decreases expression |
EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CCNE1 protein] |
CTD |
PMID:26577051 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA] Simvastatin results in decreased expression of CCR1 mRNA |
CTD |
PMID:16321392 PMID:16414398 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions decreases expression |
ISO EXP |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA] Simvastatin results in decreased expression of CCR2 mRNA; Simvastatin results in decreased expression of CCR2 protein |
CTD |
PMID:15781755 PMID:16321392 PMID:16414398 PMID:16781696 PMID:17449418 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA] |
CTD |
PMID:16321392 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA] Simvastatin results in decreased expression of CCR5 mRNA Simvastatin results in decreased expression of CCR5 protein |
CTD |
PMID:16321392 PMID:17112859 PMID:17449418 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD14 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd151 |
CD151 molecule (Raph blood group) |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD151 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 1:196,564,744...196,568,753
Ensembl chr 1:196,565,181...196,568,753
|
|
G |
Cd24 |
CD24 molecule |
increases expression |
ISO |
Simvastatin results in increased expression of CD24 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd27 |
CD27 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD27 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
|
|
G |
Cd2ap |
CD2-associated protein |
increases expression |
ISO |
Simvastatin results in increased expression of CD2AP mRNA |
CTD |
PMID:16710349 |
|
NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199
|
|
G |
Cd40 |
CD40 molecule |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CD40 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]] |
CTD |
PMID:16387846 PMID:17169357 PMID:17507688 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression increases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CD40LG protein; Simvastatin results in decreased expression of CD40LG protein modified form Simvastatin results in increased expression of CD40LG protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA] |
CTD |
PMID:17169357 PMID:18269829 PMID:21330348 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CD44 protein]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter] Simvastatin results in decreased expression of CD44 mRNA; Simvastatin results in decreased expression of CD44 protein |
CTD |
PMID:21199873 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd80 |
Cd80 molecule |
decreases expression |
EXP |
Simvastatin results in decreased expression of CD80 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD83 protein |
CTD |
PMID:16387846 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
Simvastatin results in decreased expression of CD86 protein |
CTD |
PMID:16387846 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc25b |
cell division cycle 25B |
affects expression |
ISO |
Simvastatin affects the expression of CDC25B mRNA; Simvastatin affects the expression of CDC25B protein |
CTD |
PMID:19110722 |
|
NCBI chr 3:118,407,127...118,417,272
Ensembl chr 3:118,407,128...118,417,272
|
|
G |
Cdc42 |
cell division cycle 42 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CDC42 protein |
CTD |
PMID:17169357 |
|
NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDC45 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDC6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdh5 |
cadherin 5 |
increases expression |
EXP |
Simvastatin results in increased expression of CDH5 mRNA; Simvastatin results in increased expression of CDH5 protein |
CTD |
PMID:19109527 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of CDK1 mRNA; Simvastatin results in decreased expression of CDK1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK1 protein] |
CTD |
PMID:17428261 PMID:20878096 PMID:26577051 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; [Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in decreased activity of CDK2 protein Simvastatin results in decreased expression of CDK2 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of CDK2 protein] |
CTD |
PMID:10412745 PMID:17928568 PMID:18804536 PMID:20878096 PMID:26577051 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression decreases activity |
ISO EXP |
Simvastatin results in decreased expression of CDK4 protein Simvastatin results in decreased activity of CDK4 protein |
CTD |
PMID:18804536 PMID:20878096 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
increases expression |
ISO |
Simvastatin results in increased expression of CDK5 |
CTD |
PMID:19461118 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
[Simvastatin results in decreased degradation of CDKN1A protein] which results in decreased activity of CDK2 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of CDKN1A protein]; Simvastatin inhibits the reaction [Fluorouracil results in decreased degradation of CDKN1A protein] Simvastatin results in increased expression of CDKN1A mRNA; Simvastatin results in increased expression of CDKN1A protein |
CTD |
PMID:15625077 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18625202 PMID:18804536 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO EXP |
[Simvastatin results in decreased degradation of CDKN1B protein] which results in decreased activity of CDK2 protein Simvastatin results in increased expression of CDKN1B mRNA; Simvastatin results in increased expression of CDKN1B protein |
CTD |
PMID:12963647 PMID:17428261 PMID:17928568 PMID:18337644 PMID:18804536 PMID:20878096 More...
|
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN1C mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
EXP |
Simvastatin results in increased expression of CDKN2A protein |
CTD |
PMID:18804536 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
increases expression |
ISO |
Simvastatin results in increased expression of CDKN2D mRNA; Simvastatin results in increased expression of CDKN2D protein |
CTD |
PMID:20878096 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CDT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr 6:16,119,871...16,137,600
Ensembl chr 6:16,119,872...16,137,600
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
EXP ISO |
Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of CES1 protein] Simvastatin inhibits the reaction [CES1 protein results in increased hydrolysis of remdesivir] |
CTD |
PMID:33383043 PMID:34774545 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions decreases expression increases expression |
ISO |
Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein] Simvastatin results in decreased expression of CFLAR protein; Simvastatin results in decreased expression of CFLAR protein alternative form Simvastatin results in increased expression of CFLAR mRNA; Simvastatin results in increased expression of CFLAR protein |
CTD |
PMID:17277159 PMID:18521906 PMID:19262002 PMID:21910007 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CFTR protein] |
CTD |
PMID:33774062 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA] |
CTD |
PMID:16828882 |
|
NCBI chr 3:99,284,846...99,337,252
Ensembl chr 3:99,284,846...99,337,252
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions increases phosphorylation increases expression |
ISO |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of CHUK protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of CHUK protein] Simvastatin results in increased expression of CHUK mRNA |
CTD |
PMID:18463201 PMID:19262002 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein] |
CTD |
PMID:11219190 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions decreases expression increases secretion |
ISO EXP |
[Clarithromycin co-treated with Simvastatin] results in increased expression of CKM protein Simvastatin results in decreased expression of CKM protein carvacrol inhibits the reaction [Simvastatin results in increased secretion of CKM protein]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of CKM protein] |
CTD |
PMID:8611662 PMID:19252767 PMID:29071762 PMID:35762198 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein] Simvastatin results in decreased expression of CLCN3 protein |
CTD |
PMID:20644009 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Cldn18 |
claudin 18 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of CLDN18 protein] |
CTD |
PMID:33774062 |
|
NCBI chr 8:100,246,499...100,265,797
Ensembl chr 8:100,247,633...100,273,351
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CLDN4 protein] |
CTD |
PMID:33774062 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL11A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL12A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
|
|
G |
Col13a1 |
collagen type XIII alpha 1 chain |
decreases response to substance |
ISO |
COL13A1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of COL1A1 mRNA]; Simvastatin inhibits the reaction [CEBPZ binds to COL1A1 promoter]; Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] Simvastatin results in increased expression of COL1A1 mRNA |
CTD |
PMID:10412775 PMID:14973129 PMID:16274305 PMID:16575855 PMID:17252541 PMID:20417880 More...
|
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions increases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 PMID:19912653 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression decreases expression |
ISO EXP |
Simvastatin results in increased expression of COL3A1 mRNA Simvastatin results in decreased expression of COL3A1 mRNA |
CTD |
PMID:10412775 PMID:16274305 PMID:16414398 PMID:17183729 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
ISO |
Simvastatin results in decreased expression of COL4A1 mRNA |
CTD |
PMID:10412775 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL5A1 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL6A2 mRNA |
CTD |
PMID:16274305 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col7a1 |
collagen type VII alpha 1 chain |
increases expression |
ISO |
Simvastatin results in increased expression of COL7A1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:109,604,877...109,637,249
Ensembl chr 8:109,604,861...109,637,252
|
|
G |
Coro1a |
coronin 1A |
decreases expression |
EXP |
Simvastatin results in decreased expression of CORO1A protein |
CTD |
PMID:20217863 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crp |
C-reactive protein |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of CRP protein [Ezetimibe co-treated with Simvastatin] results in decreased expression of CRP protein; [Simvastatin co-treated with Ezetimibe] promotes the reaction [Niacin results in decreased expression of CRP protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in increased expression of CRP protein]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]; Simvastatin inhibits the reaction [ethinyl estradiol-desogestrel combination results in increased expression of CRP protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of CRP protein] |
CTD |
PMID:15184351 PMID:15824212 PMID:17105841 PMID:18023360 PMID:18420099 PMID:20152243 More...
|
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cspg4 |
chondroitin sulfate proteoglycan 4 |
increases expression |
ISO |
Simvastatin results in increased expression of CSPG4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 8:57,264,962...57,300,010
Ensembl chr 8:57,264,962...57,300,010
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of AGT mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CTLA4 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO EXP |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein] Simvastatin inhibits the reaction [Glucose results in decreased expression of CTNNB1 protein] Simvastatin results in increased expression of CTNNB1 protein |
CTD |
PMID:18004065 PMID:22058016 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
Simvastatin results in increased expression of CTSL mRNA |
CTD |
PMID:19001041 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of CTSS protein] |
CTD |
PMID:20835264 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cttn |
cortactin |
affects localization multiple interactions |
ISO |
Simvastatin affects the localization of CTTN protein Simvastatin affects the reaction [F2 affects the localization of CTTN protein] |
CTD |
PMID:14630613 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CX3CR1 mRNA |
CTD |
PMID:18359719 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of CXCL10 mRNA]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of CXCL10 protein] Simvastatin results in decreased expression of CXCL10 mRNA; Simvastatin results in decreased expression of CXCL10 protein |
CTD |
PMID:15187114 PMID:16414398 PMID:17449418 PMID:22305382 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
EXP |
Simvastatin results in increased expression of CXCL12 |
CTD |
PMID:19591934 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCL16 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL2 mRNA; Simvastatin results in decreased expression of CXCL2 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of CXCL1 mRNA; Simvastatin results in decreased expression of CXCL1 protein |
CTD |
PMID:21330348 PMID:21441352 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl6 |
C-X-C motif chemokine ligand 6 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCL5 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr14:17,310,790...17,312,250
Ensembl chr14:17,310,426...17,313,093
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CXCR2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression increases expression |
EXP |
Simvastatin results in decreased expression of CXCR4 mRNA Simvastatin results in increased expression of CXCR4 |
CTD |
PMID:16414398 PMID:19591934 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
affects response to substance |
ISO |
CYBA gene SNP affects the susceptibility to Simvastatin |
CTD |
PMID:15936011 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CYBB protein] |
CTD |
PMID:30513525 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11A1 mRNA; [Simvastatin co-treated with resveratrol] results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:106,838,590...106,845,004
Ensembl chr 7:106,838,590...106,845,004
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP11B2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP |
Simvastatin results in decreased expression of CYP17A1 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of CYP17A1 mRNA; farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; resveratrol promotes the reaction [Simvastatin results in decreased expression of CYP17A1 mRNA]; Simvastatin promotes the reaction [resveratrol results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:21918126 PMID:24524197 PMID:25055962 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Simvastatin results in increased expression of CYP2B6 mRNA |
CTD |
PMID:15802384 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
ISO |
Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin] |
CTD |
PMID:22594507 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Simvastatin results in decreased activity of CYP2C8 protein |
CTD |
PMID:15601807 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:11753271 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CYP39A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:17,230,455...17,306,775
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions decreases activity decreases expression affects metabolic processing increases expression increases metabolic processing affects response to substance |
EXP ISO |
Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] Simvastatin results in decreased expression of CYP3A4 mRNA; Simvastatin results in decreased expression of CYP3A4 protein CYP3A4 protein affects the metabolism of Simvastatin Simvastatin results in increased expression of CYP3A4 mRNA CYP3A4 protein results in increased metabolism of Simvastatin [Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; ABCB1 alternative form affects the reaction [CYP3A4 polymorphism affects the susceptibility to Simvastatin]; telaprevir inhibits the reaction [CYP3A4 protein results in increased metabolism of Simvastatin] |
CTD |
PMID:12505310 PMID:15650881 PMID:16011971 PMID:17041008 PMID:19802823 PMID:24204015 PMID:24927617 PMID:30086269 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
affects response to substance |
ISO |
CYP3A5 polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:17192506 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp46a1 |
cytochrome P450, family 46, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of CYP46A1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 6:127,247,543...127,274,765
Ensembl chr 6:127,243,315...127,274,760
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases expression |
EXP |
Simvastatin results in increased expression of CYP51 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
EXP |
Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 mRNA]; Simvastatin promotes the reaction [Dietary Fats results in increased expression of CYP7A1 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
ISO |
Simvastatin results in decreased expression of DBF4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dbp |
D-box binding PAR bZIP transcription factor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of DBP mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
|
|
G |
Dcx |
doublecortin |
increases expression |
EXP |
Simvastatin results in increased expression of DCX |
CTD |
PMID:18544044 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Ddah1 |
dimethylarginine dimethylaminohydrolase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of DDAH1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 2:234,667,499...234,800,322
Ensembl chr 2:234,667,491...234,799,339
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
increases expression increases activity |
EXP |
Simvastatin results in increased expression of DGAT1 mRNA Simvastatin results in increased activity of DGAT1 protein |
CTD |
PMID:12056585 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO EXP |
Simvastatin results in increased expression of DHCR24 Simvastatin results in increased expression of DHCR24 mRNA; Simvastatin results in increased expression of DHCR24 protein |
CTD |
PMID:21987590 PMID:25055962 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects response to substance multiple interactions affects expression |
ISO EXP |
DHCR7 mutant form affects the susceptibility to Simvastatin Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA]; Simvastatin promotes the reaction [DHCR7 results in increased chemical synthesis of Cholesterol] Simvastatin inhibits the reaction [DHCR7 mutant form results in increased abundance of 7-dehydrocholesterol] [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of DHCR7 mRNA |
CTD |
PMID:15896653 PMID:16446309 PMID:19365639 PMID:25055962 PMID:28975700 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions |
ISO |
Simvastatin affects the localization of DIABLO protein DIABLO protein promotes the reaction [Simvastatin results in increased activity of CASP9 protein] |
CTD |
PMID:20045437 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 inhibits the reaction [Simvastatin results in increased expression of BGLAP mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] |
CTD |
PMID:22058016 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dll4 |
delta like canonical Notch ligand 4 |
increases expression |
EXP |
Simvastatin results in increased expression of DLL4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 3:106,317,114...106,327,004
Ensembl chr 3:106,316,986...106,326,931
|
|
G |
Dnm1l |
dynamin 1-like |
affects localization increases expression |
ISO |
Simvastatin affects the localization of DNM1L protein Simvastatin results in increased expression of DNM1L protein |
CTD |
PMID:20045437 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions increases expression |
EXP |
SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]]; SCH 23390 inhibits the reaction [Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein]]; Simvastatin promotes the reaction [[SK&F 82958 analog results in increased activity of DRD1 protein] which results in increased abundance of Cyclic AMP]; Simvastatin promotes the reaction [SK&F 82958 analog results in increased activity of DRD1 protein] Simvastatin results in increased expression of DRD1 mRNA; Simvastatin results in increased expression of DRD1 protein |
CTD |
PMID:15711596 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
increases expression |
EXP |
Simvastatin results in increased expression of DRD2 mRNA; Simvastatin results in increased expression of DRD2 protein |
CTD |
PMID:15711596 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dspp |
dentin sialophosphoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of DSPP mRNA |
CTD |
PMID:19249597 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of DUSP1 mRNA; Simvastatin results in decreased expression of DUSP1 protein |
CTD |
PMID:21080865 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of E2F1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Eaf2 |
ELL associated factor 2 |
decreases response to substance |
ISO |
EAF2 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr11:63,960,200...64,004,610
Ensembl chr11:63,960,200...64,004,610
|
|
G |
Edn1 |
endothelin 1 |
decreases secretion multiple interactions decreases expression |
ISO EXP |
Simvastatin results in decreased secretion of EDN1 protein Simvastatin inhibits the reaction [EDN1 protein results in increased expression of CLCN3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA] Simvastatin results in decreased expression of EDN1 mRNA; Simvastatin results in decreased expression of EDN1 protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of EDN1 protein]; Simvastatin results in increased expression of and results in increased secretion of EDN1 protein |
CTD |
PMID:16375908 PMID:18390205 PMID:19099753 PMID:20369390 PMID:20644009 PMID:21844074 PMID:22022327 More...
|
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of EDNRA protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of EDNRA mRNA] |
CTD |
PMID:19505368 PMID:22022327 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20359552 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of EGR1 protein |
CTD |
PMID:12818400 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation multiple interactions |
ISO |
Simvastatin results in decreased phosphorylation of EIF4EBP1 protein IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22144680 PMID:27734117 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of ENO1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 |
|
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
|
|
G |
Epha3 |
Eph receptor A3 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA3 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900
|
|
G |
Epha8 |
Eph receptor A8 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of EPHA8 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399
|
|
G |
Epo |
erythropoietin |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPO protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in decreased expression of EPOR protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA] |
CTD |
PMID:20821229 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions decreases activity |
ISO |
Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]; Simvastatin affects the reaction [F2 affects the localization of CTTN protein]; Simvastatin inhibits the reaction [F2 protein results in decreased expression of ENTPD1 protein] |
CTD |
PMID:12067895 PMID:14630613 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions decreases expression increases expression affects response to substance decreases activity |
ISO |
geranylgeraniol inhibits the reaction [Simvastatin results in decreased expression of F3]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of F3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of F3]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of F3 protein] Simvastatin results in decreased expression of F3; Simvastatin results in decreased expression of F3 mRNA; Simvastatin results in decreased expression of F3 protein Simvastatin results in increased expression of F3 mRNA; Simvastatin results in increased expression of F3 protein F3 polymorphism affects the susceptibility to Simvastatin Simvastatin results in decreased activity of F3 protein |
CTD |
PMID:9081680 PMID:10830219 PMID:12753293 PMID:12818400 PMID:15824212 PMID:17513194 PMID:18031796 PMID:18841289 PMID:19027114 More...
|
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO EXP |
Simvastatin results in increased expression of FASN mRNA |
CTD |
PMID:11728391 PMID:12056585 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbxo32 |
F-box protein 32 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of FBXO32 mRNA; Simvastatin results in increased expression of FBXO32 protein FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA] |
CTD |
PMID:19001041 PMID:25300705 PMID:27734117 PMID:33034787 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression increases activity multiple interactions |
EXP ISO |
Simvastatin results in increased expression of FDFT1 protein Simvastatin results in increased activity of FDFT1 protein resveratrol inhibits the reaction [Simvastatin results in increased expression of FDFT1 mRNA] |
CTD |
PMID:8517861 PMID:12518039 PMID:23386644 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of FDPS mRNA resveratrol inhibits the reaction [Simvastatin results in increased expression of FDPS mRNA] |
CTD |
PMID:23386644 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Dietary Fats results in increased expression of FGF19 mRNA] |
CTD |
PMID:33383043 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Simvastatin results in increased expression of FGF2 |
CTD |
PMID:20381859 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fkbp1a |
FKBP prolyl isomerase 1A |
decreases expression |
EXP |
Simvastatin results in decreased expression of FKBP1A mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
increases expression |
ISO |
Simvastatin results in increased expression of FKBP4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833
|
|
G |
Flot1 |
flotillin 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of FLOT1 protein |
CTD |
PMID:12628479 |
|
NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions increases expression |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of FLT1 mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of FLT1 protein] Simvastatin results in increased expression of FLT1 mRNA |
CTD |
PMID:19109527 PMID:20821229 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of FN1 mRNA Simvastatin results in increased expression of FN1 mRNA |
CTD |
PMID:10412775 PMID:15855201 PMID:16274305 PMID:16414398 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases localization decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of FOS mRNA] Simvastatin results in decreased localization of FOS protein FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FOS protein] Simvastatin inhibits the reaction [CTF1 results in increased expression of FOS mRNA] |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:16005304 PMID:19100119 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Simvastatin results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Foxo1 |
forkhead box O1 |
affects localization decreases phosphorylation increases phosphorylation multiple interactions decreases localization |
EXP ISO |
Simvastatin affects the localization of FOXO1 protein Simvastatin results in decreased phosphorylation of FOXO1 protein Simvastatin results in increased phosphorylation of FOXO1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in decreased localization of FOXO1 protein] farnesyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of FOXO1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of and affects the localization of FOXO1 protein] |
CTD |
PMID:12438947 PMID:18826357 PMID:19001041 PMID:33034787 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions increases phosphorylation decreases expression decreases phosphorylation affects localization |
ISO EXP |
Acetylcysteine inhibits the reaction [Simvastatin results in increased phosphorylation of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein] Simvastatin results in decreased expression of FOXO3 protein Simvastatin results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:19001041 PMID:20883752 PMID:27734117 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp3 |
forkhead box P3 |
increases expression multiple interactions affects methylation decreases expression |
ISO EXP |
Simvastatin results in increased expression of FOXP3 IL2 affects the reaction [Simvastatin results in increased expression of FOXP3]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of FOXP3] Simvastatin affects the methylation of FOXP3 promoter Simvastatin results in decreased expression of FOXP3 mRNA |
CTD |
PMID:20408897 PMID:20491794 PMID:22305382 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein]; FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 protein]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein]; FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:33034787 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Fzd2 |
frizzled class receptor 2 |
increases expression |
EXP |
Simvastatin results in increased expression of FZD2 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA |
CTD |
PMID:24204015 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression |
EXP |
Simvastatin results in decreased expression of GAPDH mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gata6 |
GATA binding protein 6 |
increases expression |
EXP |
Simvastatin results in increased expression of GATA6 mRNA; Simvastatin results in increased expression of GATA6 protein |
CTD |
PMID:19842842 |
|
NCBI chr18:2,188,121...2,219,532
Ensembl chr18:2,188,121...2,219,532
|
|
G |
Gdi2 |
GDP dissociation inhibitor 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of GDI2 protein |
CTD |
PMID:20217863 |
|
NCBI chr17:66,649,616...66,676,299
Ensembl chr17:66,649,619...66,676,366
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases expression |
EXP |
Simvastatin results in increased expression of GDNF |
CTD |
PMID:20851742 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gfra1 |
GDNF family receptor alpha 1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of GFRA1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO |
GJA1 protein affects the reaction [Simvastatin results in increased susceptibility to Etoposide]; Simvastatin affects the localization of and results in decreased phosphorylation of GJA1 protein |
CTD |
PMID:23978459 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
increases expression |
ISO |
Simvastatin results in increased expression of GJB2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Coal Ash results in increased expression of GLB1 protein] |
CTD |
PMID:26773838 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of GPX1 mRNA Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20883752 PMID:28734741 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
increases expression |
EXP |
Simvastatin results in increased expression of GPX2 mRNA |
CTD |
PMID:18787804 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of GSK3B Simvastatin inhibits the reaction [Glucose results in decreased phosphorylation of and results in increased activity of GSK3B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GSK3B protein] Simvastatin results in increased expression of GSK3B protein modified form |
CTD |
PMID:18004065 PMID:18047562 PMID:19461118 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] |
CTD |
PMID:23769903 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of H2AX protein |
CTD |
PMID:20499237 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hes5 |
hes family bHLH transcription factor 5 |
increases expression |
EXP |
Simvastatin results in increased expression of HES5 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 5:165,522,138...165,523,684
Ensembl chr 5:165,522,234...165,523,001
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression multiple interactions decreases expression |
ISO EXP |
Simvastatin results in increased expression of HIF1A protein HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA] Simvastatin results in decreased expression of HIF1A mRNA |
CTD |
PMID:18356691 PMID:21844074 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP ISO |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholecalciferol] results in increased expression of HMGB1 mRNA] [Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] results in increased secretion of HMGB1 protein] |
CTD |
PMID:20519084 PMID:25412314 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance affects response to substance increases activity multiple interactions increases expression decreases activity |
ISO EXP |
HMGCR exon alternative form results in decreased susceptibility to Simvastatin HMGCR intron polymorphism affects the susceptibility to Simvastatin; HMGCR polymorphism affects the susceptibility to Simvastatin Simvastatin results in increased activity of HMGCR protein [HMGCR intron polymorphism affects the expression of HMGCR exon alternative form] which results in decreased susceptibility to Simvastatin; [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; [Simvastatin co-treated with Ezetimibe] results in increased expression of HMGCR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; Resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; Resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA]; Simvastatin results in increased expression of and results in increased activity of HMGCR protein Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Mevalonic Acid inhibits the reaction [Simvastatin results in increased activity of HMGCR protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR mRNA]; resveratrol inhibits the reaction [Simvastatin results in increased expression of HMGCR protein]; resveratrol promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; Simvastatin results in increased expression of and results in decreased activity of HMGCR protein; Simvastatin results in increased expression of and results in increased activity of HMGCR protein Simvastatin results in increased expression of HMGCR mRNA; Simvastatin results in increased expression of HMGCR protein |
CTD |
PMID:1627634 PMID:8517861 PMID:8593127 PMID:9512650 PMID:10357840 PMID:12056585 PMID:12477733 PMID:12518039 PMID:16282522 PMID:17870053 PMID:17980884 PMID:18332269 PMID:18559695 PMID:19383813 PMID:20413733 PMID:21257924 PMID:21907337 PMID:22120639 PMID:23386644 PMID:24524197 PMID:24613879 PMID:25055962 PMID:28975700 PMID:29969672 More...
|
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases stability decreases expression increases activity increases expression increases response to substance |
ISO EXP |
[[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]]; zinc protoporphyrin inhibits the reaction [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein]; zinc protoporphyrin inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 protein]] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased abundance of Superoxides; [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; [Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein; tin protoporphyrin IX inhibits the reaction [Simvastatin results in increased expression of HMOX1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin results in increased stability of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA] Simvastatin results in decreased expression of HMOX1 mRNA Simvastatin results in increased activity of HMOX1 protein Simvastatin results in increased expression of HMOX1 mRNA; Simvastatin results in increased expression of HMOX1 protein HMOX1 gene mutant form results in increased susceptibility to Simvastatin |
CTD |
PMID:16375908 PMID:16414398 PMID:16628357 PMID:17928392 PMID:18073186 PMID:18787804 PMID:20368269 PMID:20594940 PMID:21844074 PMID:21910007 PMID:21925249 PMID:21968084 PMID:30513525 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
increases expression |
ISO |
Simvastatin results in increased expression of HNF1A mRNA |
CTD |
PMID:22160096 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions decreases activity |
ISO |
Farnesol inhibits the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of HRAS protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of HRAS protein]; Simvastatin results in decreased prenylation of and results in decreased localization of HRAS protein Simvastatin results in decreased activity of HRAS |
CTD |
PMID:11914545 PMID:12477733 PMID:18625914 PMID:19360310 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with resveratrol] results in decreased expression of HSD3B1 mRNA |
CTD |
PMID:24524197 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
affects localization |
ISO |
Simvastatin affects the localization of HSF1 protein |
CTD |
PMID:16375908 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
ISO |
Simvastatin results in increased expression of HSP90AA1 protein |
CTD |
PMID:16375908 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression |
ISO |
Simvastatin results in increased expression of HSPA4 protein |
CTD |
PMID:16375908 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
Simvastatin results in increased expression of HSPA5 mRNA; Simvastatin results in increased expression of HSPA5 protein |
CTD |
PMID:18664198 PMID:19253821 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
EXP |
Simvastatin results in decreased expression of HSPA8 protein |
CTD |
PMID:20217863 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
Simvastatin affects the localization of HTRA2 protein |
CTD |
PMID:20045437 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Ibsp |
integrin-binding sialoprotein |
increases expression |
ISO |
Simvastatin results in increased expression of IBSP mRNA |
CTD |
PMID:20417880 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Simvastatin affects the expression of and affects the secretion of ICAM1 protein; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of ICAM1 protein modified form] Simvastatin results in decreased expression of ICAM1 mRNA; Simvastatin results in decreased expression of ICAM1 protein; Simvastatin results in decreased expression of ICAM1 protein modified form |
CTD |
PMID:10946302 PMID:12615677 PMID:14602771 PMID:15234187 PMID:16054375 PMID:16193989 PMID:17277159 PMID:19166837 PMID:20863785 PMID:21764683 PMID:21874229 PMID:21994025 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Simvastatin results in increased expression of ID1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
EXP |
Simvastatin results in increased expression of IDI1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of IDO1 |
CTD |
PMID:20491794 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases expression increases secretion |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL3 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR2 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CCR5 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CIITA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL3 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased secretion of CCL4 mRNA] Simvastatin results in increased expression of IFNG mRNA Simvastatin results in increased secretion of IFNG protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of CD40 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] |
CTD |
PMID:11219190 PMID:16321392 PMID:17507688 PMID:18453621 PMID:19589242 PMID:19886038 PMID:21268089 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; IGF1 protein inhibits the reaction [Simvastatin affects the localization of FOXO3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of AKT1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of BAD protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of EIF4EBP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of CASP3 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of FBXO32 mRNA]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of AKT1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein] |
CTD |
PMID:17327694 PMID:27734117 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
decreases expression increases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of IGF1R; Simvastatin results in decreased expression of IGF1R mRNA; Simvastatin results in decreased expression of IGF1R protein Simvastatin results in increased expression of IGF1R protein alternative form [Simvastatin co-treated with NVP-AEW541] inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein]; Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IGF1R protein] |
CTD |
PMID:17158816 PMID:17327694 PMID:18489904 PMID:27734117 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Igfbp6 |
insulin-like growth factor binding protein 6 |
increases expression |
ISO |
Simvastatin results in increased expression of IGFBP6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases expression increases phosphorylation |
ISO |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of IKBKB protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of IKBKB protein] Simvastatin results in decreased expression of IKBKB mRNA |
CTD |
PMID:17277159 PMID:18463201 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
increases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of IL10 Simvastatin results in increased expression of IL10 mRNA; Simvastatin results in increased expression of IL10 protein Simvastatin promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein] 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of IL10 protein] |
CTD |
PMID:15883752 PMID:20491794 PMID:21925249 PMID:33774062 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
FOS inhibits the reaction [Simvastatin results in increased expression of IL12B mRNA]; JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B mRNA]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL12B protein]; Simvastatin promotes the reaction [Pam(3)CSK(4) peptide results in increased expression of IL12B protein]; Simvastatin promotes the reaction [resiquimod results in increased expression of IL12B protein] |
CTD |
PMID:15187114 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
decreases expression |
ISO |
Simvastatin results in decreased expression of IL13 mRNA; Simvastatin results in decreased expression of IL13 protein |
CTD |
PMID:17169357 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il16 |
interleukin 16 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of IL16 mRNA |
CTD |
PMID:15665042 |
|
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
|
|
G |
Il17a |
interleukin 17A |
multiple interactions decreases expression decreases secretion |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IFNG affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL17A mRNA] |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il17f |
interleukin 17F |
decreases secretion |
ISO |
Simvastatin results in decreased secretion of IL17F protein |
CTD |
PMID:21856936 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
EXP ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]]; Simvastatin inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA] Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL18 protein] |
CTD |
PMID:18660453 PMID:27377765 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased abundance of Nitric Oxide]] |
CTD |
PMID:15705589 PMID:15728660 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases secretion |
EXP ISO |
1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B mRNA]; Simvastatin affects the reaction [Doxorubicin results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL1B protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of IL1B mRNA] farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [CCN1 results in increased expression of IL1B]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of ICAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] Simvastatin results in decreased expression of IL1B mRNA; Simvastatin results in decreased expression of IL1B protein Simvastatin results in decreased secretion of IL1B protein |
CTD |
PMID:10946302 PMID:12829860 PMID:15883752 PMID:16054375 PMID:17075836 PMID:18047562 PMID:18309148 PMID:18791746 PMID:19166837 PMID:19574840 PMID:20126887 PMID:20191585 PMID:21910007 PMID:22305382 PMID:27377765 PMID:30408459 PMID:31260663 PMID:33774062 PMID:35762198 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL1R2 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL1RL1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
IL2 affects the reaction [Simvastatin results in increased expression of FOXP3] |
CTD |
PMID:20408897 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression |
ISO |
Simvastatin results in increased expression of IL20RB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Il21 |
interleukin 21 |
decreases expression decreases secretion |
ISO |
Simvastatin results in decreased expression of IL21 mRNA Simvastatin results in decreased secretion of IL21 protein |
CTD |
PMID:18453621 PMID:21856936 |
|
NCBI chr 2:120,117,105...120,127,012
Ensembl chr 2:120,119,444...120,126,996
|
|
G |
Il22 |
interleukin 22 |
decreases secretion |
ISO |
Simvastatin results in decreased secretion of IL22 protein |
CTD |
PMID:21856936 |
|
NCBI chr 7:53,801,206...53,805,673
Ensembl chr 7:53,801,206...53,806,186
|
|
G |
Il23a |
interleukin 23 subunit alpha |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of IL23A mRNA |
CTD |
PMID:18453621 PMID:22305382 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il25 |
interleukin 25 |
decreases expression |
EXP |
Simvastatin results in decreased expression of IL25 mRNA |
CTD |
PMID:22305382 |
|
NCBI chr15:28,408,766...28,412,157
Ensembl chr15:28,408,842...28,411,893
|
|
G |
Il27 |
interleukin 27 |
increases expression multiple interactions increases secretion |
ISO |
Simvastatin results in increased expression of IL27 mRNA IL27 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] Simvastatin results in increased secretion of IL27 protein |
CTD |
PMID:18453621 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
affects expression decreases expression |
ISO |
Simvastatin affects the expression of IL2RA protein Simvastatin results in decreased expression of IL2RA mRNA |
CTD |
PMID:16387846 PMID:18453621 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression increases secretion decreases expression |
ISO |
IL4 affects the reaction [Simvastatin results in decreased expression of IL17A mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased secretion of IL17A protein] Simvastatin results in increased expression of IL4 mRNA Simvastatin results in increased secretion of IL4 protein Simvastatin results in decreased expression of IL4 mRNA; Simvastatin results in decreased expression of IL4 protein |
CTD |
PMID:17169357 PMID:18453621 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il4r |
interleukin 4 receptor |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of IL4R mRNA Simvastatin results in decreased expression of IL4RA mRNA |
CTD |
PMID:16414398 PMID:18453621 |
|
NCBI chr 1:180,115,061...180,139,981
Ensembl chr 1:180,115,120...180,139,980
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression decreases expression decreases secretion affects secretion |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IL6 mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Simvastatin results in decreased expression of and results in decreased secretion of IL6 protein Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of IL6 protein] Simvastatin results in increased expression of IL6 mRNA geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein] Simvastatin results in decreased expression of IL6 mRNA; Simvastatin results in decreased expression of IL6 protein Simvastatin results in decreased secretion of IL6 protein Simvastatin affects the secretion of IL6 protein |
CTD |
PMID:12117737 PMID:15665042 PMID:15883752 PMID:16387846 PMID:16424782 PMID:16511915 PMID:17075836 PMID:17641834 PMID:17729120 PMID:18203325 PMID:18453621 PMID:18504409 PMID:19001041 PMID:19166837 PMID:20065508 PMID:20126887 PMID:21994025 PMID:22305382 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inha |
inhibin subunit alpha |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INHA mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248
|
|
G |
Insig2 |
insulin induced gene 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of INSIG2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr13:32,472,390...32,500,139
Ensembl chr13:32,473,742...32,494,923
|
|
G |
Insl3 |
insulin-like 3 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of INSL3 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr16:18,398,682...18,400,566
Ensembl chr16:18,384,829...18,400,560
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IFNG results in increased expression of IRF1 mRNA] |
CTD |
PMID:17507688 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Irf4 |
interferon regulatory factor 4 |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of IRF4 protein Simvastatin results in decreased expression of IRF4 mRNA; Simvastatin results in decreased expression of IRF4 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of IRF4 protein] |
CTD |
PMID:21856936 PMID:33034787 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [IGF1 protein results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itgal |
integrin subunit alpha L |
affects binding multiple interactions decreases expression |
ISO |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the activity of CHAT protein]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHAT mRNA]; Simvastatin inhibits the reaction [ITGAL affects the susceptibility to and affects the expression of CHRM5 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL] Simvastatin results in decreased expression of ITGAL mRNA |
CTD |
PMID:12615677 PMID:15041742 PMID:16828882 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Itgam |
integrin subunit alpha M |
decreases expression multiple interactions |
ISO EXP |
Simvastatin results in decreased expression of ITGAM mRNA; Simvastatin results in decreased expression of ITGAM protein Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] |
CTD |
PMID:16414398 PMID:21330348 PMID:21441352 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGB1 mRNA; Simvastatin results in decreased expression of ITGB1 protein |
CTD |
PMID:17428261 PMID:21874229 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
affects binding multiple interactions decreases expression |
ISO |
Simvastatin binds to [ITGAL protein binds to ITGB2 protein] Simvastatin results in decreased expression of [ITGAM protein binds to ITGB2 protein] Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2] Simvastatin results in decreased expression of ITGB2 mRNA |
CTD |
PMID:12615677 PMID:15041742 PMID:21330348 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Itgb3bp |
integrin subunit beta 3 binding protein |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGB3BP mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704
|
|
G |
Itgb4 |
integrin subunit beta 4 |
affects expression increases expression |
ISO |
Simvastatin affects the expression of ITGB4 mRNA; Simvastatin affects the expression of ITGB4 protein Simvastatin results in increased expression of ITGB4 mRNA; Simvastatin results in increased expression of ITGB4 protein |
CTD |
PMID:14630613 PMID:19110722 |
|
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Itgbl1 |
integrin subunit beta like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733
|
|
G |
Jak1 |
Janus kinase 1 |
multiple interactions |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK1 protein] |
CTD |
PMID:16534557 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions decreases expression decreases phosphorylation |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of JAK2 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of JAK2 protein] Simvastatin results in decreased expression of JAK2 mRNA Simvastatin results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:16414398 PMID:16534557 PMID:18400235 PMID:19100119 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases phosphorylation decreases localization decreases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein] JUN promotes the reaction [Simvastatin results in increased expression of IL12B mRNA]; Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]]; Simvastatin promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of JUN protein] Simvastatin results in decreased localization of JUN protein Simvastatin results in decreased expression of JUN mRNA |
CTD |
PMID:12753293 PMID:12963647 PMID:15187114 PMID:15488325 PMID:17125918 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Simvastatin affects the reaction [lipopolysaccharide, E coli O55-B5 promotes the reaction [JUN protein binds to JUNB protein binds to FOS protein binds to FOSB protein binds to FOSL2 protein]] |
CTD |
PMID:15187114 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases localization decreases activity multiple interactions |
EXP |
Simvastatin results in decreased localization of KCNH2 protein Simvastatin results in decreased activity of KCNH2 protein Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:21525004 PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of KDR mRNA; Simvastatin results in increased expression of KDR protein Simvastatin inhibits the reaction [Streptozocin results in increased expression of KDR mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of and results in increased expression of KDR protein] |
CTD |
PMID:15572054 PMID:19109527 PMID:20821229 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of KIT mRNA |
CTD |
PMID:28263720 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klf10 |
KLF transcription factor 10 |
multiple interactions |
ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [AGT protein results in increased expression of KLF10 mRNA] |
CTD |
PMID:19225232 |
|
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
|
|
G |
Klf16 |
KLF transcription factor 16 |
increases expression |
ISO |
Simvastatin results in increased expression of KLF16 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 7:9,138,503...9,148,322
Ensembl chr 7:9,138,503...9,148,317
|
|
G |
Klf2 |
KLF transcription factor 2 |
increases expression multiple interactions decreases expression |
ISO EXP |
Simvastatin results in increased expression of KLF2 mRNA Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of KLF2 mRNA] Simvastatin results in decreased expression of KLF2 mRNA |
CTD |
PMID:17428261 PMID:20493886 PMID:20737288 PMID:22305382 |
|
NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression |
ISO |
Simvastatin results in increased expression of KLF6 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klrb1 |
killer cell lectin like receptor B1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of KLRF1 mRNA |
CTD |
PMID:18192897 |
|
NCBI chr 4:162,456,294...162,474,989
Ensembl chr 4:162,456,294...162,474,989
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases prenylation |
ISO |
Simvastatin results in decreased prenylation of KRAS protein |
CTD |
PMID:8063617 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Krt13 |
keratin 13 |
increases expression |
ISO |
Simvastatin results in increased expression of KRT13 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,051,889...85,056,084
|
|
G |
Krt15 |
keratin 15 |
increases expression |
ISO |
Simvastatin results in increased expression of KRT15 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt17 |
keratin 17 |
increases expression |
ISO |
Simvastatin results in increased expression of KRT17 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
|
|
G |
Lbh |
LBH regulator of WNT signaling pathway |
increases expression |
ISO |
Simvastatin results in increased expression of LBH mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 6:22,569,238...22,593,056
Ensembl chr 6:22,568,834...22,593,079
|
|
G |
Lbp |
lipopolysaccharide binding protein |
decreases expression |
EXP |
Simvastatin results in decreased expression of LBP mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
increases activity decreases expression |
ISO EXP |
Simvastatin results in increased activity of LCAT protein Simvastatin results in decreased expression of LCAT mRNA |
CTD |
PMID:21241519 PMID:25055962 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions affects response to substance increases expression increases activity |
ISO EXP |
[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB; [Simvastatin co-treated with Ezetimibe] results in increased expression of LDLR mRNA; HMGCR polymorphism promotes the reaction [[LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin] which affects the expression of APOB] LDLR 3' UTR polymorphism affects the susceptibility to Simvastatin; LDLR mutant form affects the susceptibility to Simvastatin Simvastatin results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] Simvastatin results in increased activity of LDLR protein Simvastatin results in increased expression of LDLR mRNA; Simvastatin results in increased expression of LDLR protein |
CTD |
PMID:1627634 PMID:8457250 PMID:8593127 PMID:9633944 PMID:10208479 PMID:10357840 PMID:11181283 PMID:11600564 PMID:11728391 PMID:11849659 PMID:17980884 PMID:18640378 PMID:19383813 PMID:20018177 PMID:20413733 PMID:22120639 More...
|
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
increases expression |
EXP |
Simvastatin results in increased expression of LEF1 mRNA |
CTD |
PMID:19968183 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Lep |
leptin |
multiple interactions decreases expression decreases secretion |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; GGTI 298 inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; GGTI 298 inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of LEP protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Simvastatin results in decreased expression of LEP mRNA] Simvastatin results in decreased expression of LEP mRNA; Simvastatin results in decreased expression of LEP mRNA alternative form Simvastatin inhibits the reaction [Poloxamer results in increased secretion of LEP protein] |
CTD |
PMID:19254925 PMID:29071762 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
affects response to substance |
ISO |
LEPR polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:14625131 PMID:18854995 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lhb |
luteinizing hormone subunit beta |
multiple interactions |
ISO |
Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of LHB protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of LHB protein] |
CTD |
PMID:17105841 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
[Valsartan co-treated with Simvastatin] inhibits the reaction [Glucose promotes the reaction [AGT protein results in increased expression of LIF mRNA]] |
CTD |
PMID:19225232 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
decreases expression |
EXP |
Simvastatin results in decreased expression of LITAF mRNA |
CTD |
PMID:16414398 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
EXP |
Simvastatin results in decreased expression of LOX mRNA |
CTD |
PMID:16414398 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Lpl |
lipoprotein lipase |
decreases expression increases expression |
EXP |
Simvastatin results in decreased expression of LPL Simvastatin results in increased expression of LPL protein |
CTD |
PMID:2009092 PMID:19216230 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp6 |
LDL receptor related protein 6 |
decreases expression |
EXP |
Simvastatin results in decreased expression of LRP6 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 4:167,269,856...167,400,364
Ensembl chr 4:167,270,353...167,400,497
|
|
G |
Lrrc2 |
leucine rich repeat containing 2 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of LRRC2 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 8:110,936,119...110,969,189
Ensembl chr 8:110,938,165...110,969,185
|
|
G |
Ltb |
lymphotoxin beta |
decreases expression |
ISO |
Simvastatin results in decreased expression of LTB mRNA |
CTD |
PMID:17428261 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MAD2L1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of MAP1LC3B protein [Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form; Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:23817226 PMID:25412314 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map3k14 |
mitogen-activated protein kinase kinase kinase 14 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MAP3K14 mRNA |
CTD |
PMID:17277159 |
|
NCBI chr10:88,165,349...88,215,558
Ensembl chr10:88,165,351...88,215,523
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
multiple interactions |
ISO |
Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein] |
CTD |
PMID:17277159 |
|
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]]; MAPK1 promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein Simvastatin results in decreased activity of MAPK1 protein Simvastatin results in increased phosphorylation of MAPK1 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK1 protein Simvastatin results in decreased phosphorylation of MAPK1 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK1 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK1 protein |
CTD |
PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 PMID:18310456 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19383813 PMID:20359552 PMID:20417880 PMID:20464445 PMID:20594940 PMID:21080865 PMID:21910007 PMID:30513525 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions decreases expression |
ISO EXP |
Simvastatin results in increased phosphorylation of and results in increased activity of MAPK14 protein Simvastatin results in decreased expression of MAPK14 mRNA |
CTD |
PMID:16414398 PMID:17928392 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases activity increases phosphorylation decreases phosphorylation |
ISO EXP |
[tipifarnib co-treated with Simvastatin] results in decreased phosphorylation of MAPK3 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein Simvastatin results in decreased activity of MAPK3 protein Simvastatin results in increased phosphorylation of MAPK3 protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [IGF1 results in increased activity of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin results in increased phosphorylation of and results in increased activity of MAPK3 protein Simvastatin results in decreased phosphorylation of MAPK3 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]]; Simvastatin inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of MAPK3 protein]; Simvastatin results in decreased phosphorylation of and results in decreased activity of MAPK3 protein |
CTD |
PMID:17169357 PMID:17327694 PMID:17428261 PMID:17928392 PMID:18047562 PMID:18310456 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19383813 PMID:20359552 PMID:20417880 PMID:20464445 PMID:20594940 PMID:21080865 PMID:21910007 PMID:30513525 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases activity |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein] Simvastatin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein] Simvastatin results in increased activity of MAPK8 protein |
CTD |
PMID:15187114 PMID:18047562 PMID:18310456 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases activity |
ISO |
Simvastatin results in increased activity of MAPK9 protein |
CTD |
PMID:15187114 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
affects expression |
ISO |
Simvastatin affects the expression of MAPT |
CTD |
PMID:19461118 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mb |
myoglobin |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Poloxamer results in increased secretion of MB protein] |
CTD |
PMID:29071762 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mcm4 |
minichromosome maintenance complex component 4 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MCM4 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MDH1 protein |
CTD |
PMID:20217863 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases phosphorylation multiple interactions |
ISO |
Simvastatin results in increased phosphorylation of MDM2 protein Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]] |
CTD |
PMID:15625077 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of MERTK mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Mir221 |
microRNA 221 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MIR221 |
CTD |
PMID:25517390 |
|
NCBI chr X:3,429,465...3,429,573
Ensembl chr X:3,429,465...3,429,573
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
EXP |
Simvastatin results in decreased expression of MKI67 protein |
CTD |
PMID:26577051 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions decreases expression decreases secretion increases expression |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of MMP1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased secretion of MMP1 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP1 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MMP1 protein] Simvastatin results in decreased secretion of MMP1 mRNA; Simvastatin results in decreased secretion of MMP1 protein Simvastatin results in increased expression of MMP1 mRNA |
CTD |
PMID:17303772 PMID:17428261 PMID:18625914 PMID:31260663 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp10 |
matrix metallopeptidase 10 |
increases expression |
ISO |
Simvastatin results in increased expression of MMP10 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Simvastatin results in increased expression of MMP12 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of MMP13 mRNA Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP13 mRNA] |
CTD |
PMID:16274305 PMID:17428261 PMID:31260663 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity increases activity multiple interactions decreases expression |
ISO EXP |
Simvastatin results in decreased activity of MMP2 protein Simvastatin results in increased activity of MMP2 protein Simvastatin inhibits the reaction [Monocrotaline results in increased expression of MMP2 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP2 protein Simvastatin affects the reaction [IL1B protein results in increased activity of MMP2 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 protein] Simvastatin results in decreased expression of MMP2 mRNA Simvastatin results in decreased expression of MMP2 protein |
CTD |
PMID:15210533 PMID:17038636 PMID:17158816 PMID:17169357 PMID:18309148 PMID:19360310 PMID:22022327 PMID:23831763 PMID:31260663 More...
|
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp28 |
matrix metallopeptidase 28 |
increases expression |
ISO |
Simvastatin results in increased expression of MMP28 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:68,241,138...68,264,866
Ensembl chr10:68,241,138...68,264,866
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
decreases expression multiple interactions |
EXP ISO |
Simvastatin results in decreased expression of MMP3 mRNA Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP3 mRNA] |
CTD |
PMID:16414398 PMID:31260663 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP8 mRNA] |
CTD |
PMID:18625914 |
|
NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity decreases activity decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [IL1B protein results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA] Simvastatin results in increased activity of MMP9 protein Simvastatin results in decreased activity of MMP9 protein Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of MMP9 protein] farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MMP9 protein]; Simvastatin inhibits the reaction [Smoke analog results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [Smoke analog results in increased secretion of MMP9 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of MMP9 mRNA]; Simvastatin results in decreased expression of and results in decreased activity of MMP9 protein Simvastatin results in decreased expression of MMP9 protein Simvastatin results in decreased expression of MMP9 mRNA; Simvastatin results in decreased expression of MMP9 protein |
CTD |
PMID:15107580 PMID:15210533 PMID:15537504 PMID:15728660 PMID:16002570 PMID:16414398 PMID:17038636 PMID:17169357 PMID:17277159 PMID:17560598 PMID:18309148 PMID:18569431 PMID:18625914 PMID:19299917 PMID:19360310 PMID:19505368 PMID:19589242 PMID:19820293 PMID:20835264 PMID:23831763 PMID:31260663 More...
|
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases expression decreases activity |
ISO EXP |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] Simvastatin results in decreased expression of MPO protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] Simvastatin results in decreased activity of MPO protein 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein]]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of MPO protein] |
CTD |
PMID:15665042 PMID:17038636 PMID:21764683 PMID:33774062 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mras |
muscle RAS oncogene homolog |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Glucose results in increased activity of MRAS protein]; Simvastatin inhibits the reaction [Smoke analog results in increased activity of MRAS protein] |
CTD |
PMID:18569938 PMID:19299917 |
|
NCBI chr 8:99,944,036...100,006,771
Ensembl chr 8:99,944,036...99,996,408
|
|
G |
Mrps31 |
mitochondrial ribosomal protein S31 |
decreases response to substance |
ISO |
MRPS31 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr16:69,601,349...69,621,609
Ensembl chr16:69,601,349...69,630,654
|
|
G |
Mstn |
myostatin |
multiple interactions increases expression |
ISO |
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; IRF4 protein inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of MSTN protein]; Simvastatin results in increased expression of and results in increased secretion of MSTN protein Simvastatin results in increased expression of MSTN mRNA; Simvastatin results in increased expression of MSTN protein |
CTD |
PMID:33034787 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
EXP |
Simvastatin results in increased expression of MT1A mRNA |
CTD |
PMID:19001041 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
multiple interactions increases expression affects response to substance |
ISO |
Homocysteine inhibits the reaction [Simvastatin results in increased expression of MTHFR protein modified form]; Simvastatin promotes the reaction [Homocysteine results in increased expression of MTHFR protein] MTHFR affects the susceptibility to Simvastatin MTHFR gene mutant form inhibits the reaction [Simvastatin results in increased expression of APOA1 protein]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein] |
CTD |
PMID:18540024 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
Simvastatin results in decreased phosphorylation of MTOR protein FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:22144680 PMID:33034787 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
EXP ISO |
Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of MUC5AC mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of MUC5AC protein] Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein]]; Simvastatin inhibits the reaction [Acrolein results in increased expression of MUC5AC protein] |
CTD |
PMID:19024099 PMID:20359552 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases expression |
EXP |
Simvastatin results in increased expression of MVD mRNA |
CTD |
PMID:25055962 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Mvk |
mevalonate kinase |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of MVK mRNA [MVK gene mutant form results in increased activity of HMGCR protein] which results in increased susceptibility to Simvastatin; MVK gene mutant form promotes the reaction [Simvastatin results in decreased activity of HMGCR protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased farnesylation of and affects the localization of HRAS protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein] |
CTD |
PMID:12477733 PMID:25055962 |
|
NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Mybph |
myosin binding protein H |
increases expression |
ISO |
Simvastatin results in increased expression of MYBPH mRNA |
CTD |
PMID:17183729 |
|
NCBI chr13:45,653,156...45,660,893
Ensembl chr13:45,653,234...45,660,893
|
|
G |
Myh10 |
myosin heavy chain 10 |
decreases expression |
ISO |
Simvastatin results in decreased expression of MYH10 protein |
CTD |
PMID:16005304 |
|
NCBI chr10:53,393,901...53,525,174
Ensembl chr10:53,394,389...53,525,165
|
|
G |
Myh6 |
myosin heavy chain 6 |
increases expression |
ISO |
Simvastatin results in increased expression of MYH6 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of NDRG1 protein |
CTD |
PMID:20217863 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
multiple interactions decreases localization increases localization |
ISO |
Simvastatin promotes the reaction [NFATC3 protein binds to BCL2 promoter] Simvastatin results in decreased localization of NFATC3 protein alternative form Simvastatin results in increased localization of NFATC3 protein |
CTD |
PMID:20369390 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases localization multiple interactions increases expression |
ISO EXP |
Simvastatin results in increased localization of NFE2L2 protein NFE2L2 mutant form inhibits the reaction [Glucose deficiency promotes the reaction [Simvastatin results in increased expression of HMOX1 mRNA]] Mevalonic Acid affects the reaction [Simvastatin results in increased localization of NFE2L2 protein] Simvastatin results in increased expression of NFE2L2 mRNA MAPK1 promotes the reaction [Simvastatin results in increased expression of NFE2L2 mRNA]; Simvastatin results in increased expression of and affects the localization of NFE2L2 protein |
CTD |
PMID:17928392 PMID:18787804 PMID:30513525 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions increases localization decreases localization decreases activity decreases expression |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of NFKB1 protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of NFKB1 protein]; Simvastatin results in increased localization of and results in increased activity of NFKB1 protein Simvastatin results in decreased localization of NFKB1 protein Simvastatin results in decreased activity of NFKB1 protein Simvastatin results in decreased expression of NFKB1 mRNA Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]] |
CTD |
PMID:12753293 PMID:17038636 PMID:17277159 PMID:18463201 PMID:21465237 PMID:21925249 More...
|
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases phosphorylation |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; parthenolide inhibits the reaction [Simvastatin results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased phosphorylation of NFKBIA protein] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased degradation of NFKBIA protein]] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which results in increased phosphorylation of NFKBIA protein; Simvastatin inhibits the reaction [IL1A results in decreased expression of NFKBIA protein modified form]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:15705589 PMID:17075836 PMID:17178392 PMID:17277159 PMID:18073186 PMID:18463201 PMID:18826357 PMID:19299917 PMID:21925249 More...
|
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlgn3 |
neuroligin 3 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NLGN3 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr X:66,427,926...66,457,378
Ensembl chr X:66,429,458...66,451,876
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of NLRP3 mRNA]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of NLRP3 protein] |
CTD |
PMID:30408459 PMID:35762198 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
NOG inhibits the reaction [Simvastatin results in increased expression of ACAN mRNA]; NOG inhibits the reaction [Simvastatin results in increased expression of COL2A1 mRNA] |
CTD |
PMID:18628692 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
Simvastatin promotes the reaction [Doxorubicin results in increased expression of NOS2 protein] Simvastatin results in increased expression of NOS2 mRNA; Simvastatin results in increased expression of NOS2 protein Homocysteine affects the reaction [Simvastatin results in increased expression of NOS2 protein]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 mRNA]; MTHFR inhibits the reaction [Simvastatin results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; Simvastatin promotes the reaction [Homocysteine results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [IL1A results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS2 mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in decreased expression of NOS2 protein]] Simvastatin results in decreased expression of NOS2 mRNA; Simvastatin results in decreased expression of NOS2 protein |
CTD |
PMID:10188333 PMID:11470468 PMID:15705589 PMID:16414398 PMID:17729120 PMID:18047562 PMID:18309148 PMID:18463201 PMID:18540024 PMID:19505368 PMID:19729986 PMID:20452610 PMID:21844074 PMID:21925249 PMID:22022327 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression multiple interactions increases phosphorylation decreases expression |
ISO EXP |
Simvastatin results in increased expression of NOS3; Simvastatin results in increased expression of NOS3 mRNA; Simvastatin results in increased expression of NOS3 protein Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in decreased expression of NOS3 protein]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Smoke analog affects the expression of NOS3 mRNA]; Simvastatin results in increased expression of and results in increased phosphorylation of and results in increased activity of NOS3 protein Simvastatin results in increased phosphorylation of NOS3 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; [Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of NOS3 mRNA]; Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Nifedipine promotes the reaction [Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]; Simvastatin inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]; Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [[Hydrogen Peroxide results in decreased expression of NOS3 protein] which results in decreased secretion of Nitric Oxide]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 mRNA]]; Simvastatin promotes the reaction [Nifedipine inhibits the reaction [Hydrogen Peroxide results in decreased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of and results in increased expression of NOS3 protein]]; Wortmannin inhibits the reaction [Simvastatin promotes the reaction [[Hydrogen Peroxide co-treated with Nifedipine] results in increased phosphorylation of and results in increased expression of NOS3 protein]] Simvastatin results in decreased expression of NOS3 mRNA Simvastatin results in decreased expression of NOS3 mRNA; Simvastatin results in decreased expression of NOS3 protein |
CTD |
PMID:10188333 PMID:11470468 PMID:11947894 PMID:12379581 PMID:12406854 PMID:12963647 PMID:15572054 PMID:15711596 PMID:16002570 PMID:16375908 PMID:16414398 PMID:17335931 PMID:18221806 PMID:18309148 PMID:18826357 PMID:18981156 PMID:20493886 PMID:20562903 PMID:20659230 PMID:20737288 PMID:21968084 PMID:22022327 PMID:25517390 PMID:35762198 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
increases cleavage increases expression |
EXP |
Simvastatin results in increased cleavage of NOTCH1 protein Simvastatin results in increased expression of NOTCH1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Notch4 |
notch receptor 4 |
increases expression |
EXP |
Simvastatin results in increased expression of NOTCH4 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:17980884 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
increases expression |
ISO |
Simvastatin results in increased expression of NPHS2 mRNA |
CTD |
PMID:16710349 |
|
NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions decreases expression |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of NPPA mRNA] Simvastatin results in decreased expression of NPPA mRNA |
CTD |
PMID:16029635 PMID:16534557 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Simvastatin results in decreased expression of NPPB; Simvastatin results in decreased expression of NPPB protein |
CTD |
PMID:16628357 PMID:21124329 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
MAPK1 promotes the reaction [Simvastatin results in increased expression of NQO1 mRNA] Simvastatin results in increased expression of NQO1 mRNA; Simvastatin results in increased expression of NQO1 protein |
CTD |
PMID:30513525 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
multiple interactions |
EXP |
[Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of NR0B1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:50,756,886...50,761,014
Ensembl chr X:50,756,886...50,761,011
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of NR1D1 mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of NR1H3 mRNA |
CTD |
PMID:22160096 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 mRNA]; Simvastatin affects the reaction [Dietary Fats affects the expression of NR1H4 protein] |
CTD |
PMID:33383043 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Simvastatin results in increased activity of NR1I2 protein [Simvastatin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose; [Simvastatin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter] |
CTD |
PMID:15802384 PMID:17041008 PMID:24204015 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO EXP |
Simvastatin results in increased activity of NR1I3 protein |
CTD |
PMID:15802384 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of NR4A3 mRNA] |
CTD |
PMID:16005304 |
|
NCBI chr 5:62,361,588...62,401,489
Ensembl chr 5:62,361,822...62,402,733
|
|
G |
Nrp1 |
neuropilin 1 |
decreases response to substance |
ISO |
NRP1 SNP results in decreased susceptibility to Simvastatin |
CTD |
PMID:21483694 |
|
NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases expression |
EXP |
Simvastatin results in decreased expression of NSDHL mRNA |
CTD |
PMID:25055962 |
|
NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142
|
|
G |
Ntrk1 |
neurotrophic receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of NTRK2 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Ocln |
occludin |
increases expression |
EXP |
Simvastatin results in increased expression of OCLN |
CTD |
PMID:18544044 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of OLR1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Osbpl1a |
oxysterol binding protein-like 1A |
decreases expression |
EXP |
Simvastatin results in decreased expression of OSBPL1A mRNA |
CTD |
PMID:25055962 |
|
NCBI chr18:3,904,006...4,094,635
Ensembl chr18:3,904,006...4,094,585
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [CCN1 results in increased expression of OSM]; Simvastatin inhibits the reaction [OSM results in increased expression of CCN1 mRNA]; Simvastatin inhibits the reaction [OSM results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:20191585 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
decreases expression |
EXP |
Simvastatin results in decreased expression of P4HB mRNA |
CTD |
PMID:16414398 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases cleavage increases cleavage |
ISO EXP |
[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; pifithrin inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein]; Simvastatin inhibits the reaction [Coal Ash results in increased expression of PARP1 protein modified form]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein] Simvastatin results in decreased cleavage of PARP1 mRNA Simvastatin inhibits the reaction [Glucose results in increased activity of PARP1 protein] IGF1 protein inhibits the reaction [Simvastatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16054375 PMID:18004065 PMID:20045437 PMID:20464445 PMID:21910007 PMID:26773838 PMID:27734117 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
Simvastatin results in decreased expression of PCNA mRNA; Simvastatin results in decreased expression of PCNA protein |
CTD |
PMID:17428261 PMID:18824851 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
multiple interactions |
ISO |
[Simvastatin co-treated with Ezetimibe] results in increased expression of PCSK9 mRNA |
CTD |
PMID:17980884 |
|
NCBI chr 5:121,211,278...121,233,688
Ensembl chr 5:121,211,278...121,233,688
|
|
G |
Pde4b |
phosphodiesterase 4B |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDE4B mRNA] |
CTD |
PMID:16373842 |
|
NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
EXP |
Simvastatin results in decreased expression of PDGFA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression multiple interactions decreases activity |
EXP ISO |
Simvastatin results in decreased expression of PDGFB protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of PDGFB protein]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased expression of MMP9 mRNA]; Simvastatin inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein] Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of PDGFB mRNA] Simvastatin results in decreased expression of PDGFB mRNA |
CTD |
PMID:8231022 PMID:10412745 PMID:10412775 PMID:15728660 PMID:16373842 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
decreases expression |
EXP |
Simvastatin results in decreased expression of PDGFRA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression multiple interactions |
ISO |
Simvastatin results in decreased expression of PDGFRB mRNA [Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in increased expression of PDGFRB mRNA |
CTD |
PMID:10412775 PMID:28263720 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdk2 |
pyruvate dehydrogenase kinase 2 |
increases expression |
EXP |
Simvastatin results in increased expression of PDK2 mRNA |
CTD |
PMID:19001041 |
|
NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP ISO |
Simvastatin results in increased expression of PDK4 mRNA |
CTD |
PMID:19001041 PMID:19262002 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
Simvastatin results in increased expression of PECAM1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Phb2 |
prohibitin 2 |
decreases expression |
EXP |
Simvastatin results in decreased expression of PHB2 protein |
CTD |
PMID:20217863 |
|
NCBI chr 4:157,517,662...157,522,268
Ensembl chr 4:157,517,577...157,522,272
|
|
G |
Pigc |
phosphatidylinositol glycan anchor biosynthesis, class C |
decreases expression |
ISO |
Simvastatin results in decreased expression of PIGC mRNA |
CTD |
PMID:19262002 |
|
NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211
|
|
G |
Pitx2 |
paired-like homeodomain 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PITX2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 2:217,717,738...217,737,293
Ensembl chr 2:217,717,693...217,737,293
|
|
G |
Pkmyt1 |
protein kinase, membrane associated tyrosine/threonine 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PKMYT1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr10:12,748,221...12,758,995
Ensembl chr10:12,748,237...12,758,995
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [Cholesterol, Dietary results in increased expression of PLA2G2A protein] |
CTD |
PMID:19237014 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PLA2G7 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 mRNA] |
CTD |
PMID:21176638 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions increases expression increases activity decreases expression |
ISO EXP |
geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; geranylgeraniol inhibits the reaction [Simvastatin results in increased expression of PLAT]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT] Simvastatin results in increased expression of PLAT; Simvastatin results in increased expression of PLAT mRNA; Simvastatin results in increased expression of PLAT protein Simvastatin results in increased activity of PLAT protein Simvastatin results in decreased expression of PLAT mRNA |
CTD |
PMID:12371961 PMID:12753293 PMID:16414398 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
decreases expression |
ISO |
Simvastatin results in decreased expression of PLAU mRNA |
CTD |
PMID:10412775 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plcg2 |
phospholipase C, gamma 2 |
increases expression |
ISO |
Simvastatin results in increased expression of PLCG2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr19:45,547,416...45,683,930
Ensembl chr19:45,547,416...45,683,930
|
|
G |
Plk2 |
polo-like kinase 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PLK2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 2:41,969,176...41,974,945
Ensembl chr 2:41,969,176...41,974,947
|
|
G |
Plod3 |
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 |
decreases expression |
EXP |
Simvastatin results in decreased expression of PLOD3 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr12:19,676,384...19,686,945
Ensembl chr12:19,676,386...19,686,960
|
|
G |
Plxnd1 |
plexin D1 |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of PLXND1 mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 4:149,002,786...149,043,097
Ensembl chr 4:149,002,784...149,043,244
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
affects localization multiple interactions increases expression |
ISO |
Simvastatin affects the localization of PMAIP1 protein pifithrin inhibits the reaction [Simvastatin results in increased expression of PMAIP1 mRNA] Simvastatin results in increased expression of PMAIP1 mRNA; Simvastatin results in increased expression of PMAIP1 protein |
CTD |
PMID:20045437 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases expression |
EXP |
Simvastatin results in increased expression of PMVK mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
|
|
G |
Pomt1 |
protein-O-mannosyltransferase 1 |
increases expression |
ISO |
Simvastatin results in increased expression of POMT1 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 3:15,520,717...15,538,579
Ensembl chr 3:15,520,481...15,538,581
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions increases expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA]; PON1 gene polymorphism affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 gene SNP affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; PON1 protein affects the reaction [Simvastatin results in increased abundance of Cholesterol, HDL]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]; Simvastatin results in increased expression of and results in increased activity of PON1 protein; Squalene inhibits the reaction [Simvastatin results in increased expression of PON1 mRNA] |
CTD |
PMID:14500290 PMID:15690306 PMID:16238680 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of PPARA mRNA PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARA protein]; Simvastatin promotes the reaction [Zymosan results in increased expression of PPARA] |
CTD |
PMID:15234187 PMID:18981156 PMID:19001041 PMID:20835264 PMID:21323892 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases expression |
ISO EXP |
[2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 mRNA]; [2-chloro-5-nitrobenzanilide binds to and results in decreased activity of PPARG protein] inhibits the reaction [Simvastatin results in decreased expression of CCR2 protein] Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG mRNA]; Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of PPARG protein] Simvastatin results in decreased expression of PPARG |
CTD |
PMID:15781755 PMID:19216230 PMID:20835264 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
multiple interactions |
EXP |
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:24449418 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ppp1r14a |
protein phosphatase 1, regulatory (inhibitor) subunit 14A |
multiple interactions |
EXP |
geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased phosphorylation of PPP1R14A protein] |
CTD |
PMID:24449418 |
|
NCBI chr 1:84,583,127...84,590,743
Ensembl chr 1:84,586,627...84,590,671
|
|
G |
Prim1 |
DNA primase subunit 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of PRIM1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases expression |
EXP |
Simvastatin results in increased expression of PRKAA1 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Psen1 |
presenilin 1 |
increases expression |
EXP |
Simvastatin results in increased expression of PSEN1 mRNA |
CTD |
PMID:19109527 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Ptafr |
platelet-activating factor receptor |
decreases expression |
EXP |
Simvastatin results in decreased expression of PTAFR mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
Simvastatin results in increased expression of PTEN mRNA; Simvastatin results in increased expression of PTEN protein |
CTD |
PMID:20060890 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions decreases expression |
ISO |
Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES protein] Simvastatin results in decreased expression of PTGES protein |
CTD |
PMID:17038636 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression decreases expression |
ISO EXP |
JTE 013 inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]]; Simvastatin inhibits the reaction [IFNG results in increased expression of PTGS2]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin promotes the reaction [Glucose promotes the reaction [AGT protein results in increased expression of PTGS2 mRNA]]; Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]; Suramin inhibits the reaction [Simvastatin promotes the reaction [sphingosine 1-phosphate results in increased expression of PTGS2 mRNA]] Simvastatin results in increased expression of PTGS2 mRNA Simvastatin promotes the reaction [IFNG results in increased expression of PTGS2] Simvastatin results in decreased expression of PTGS2 protein Simvastatin inhibits the reaction [Acetic Acid results in increased expression of PTGS2 protein] |
CTD |
PMID:17038636 PMID:17277159 PMID:17901590 PMID:18612546 PMID:19225232 PMID:19886038 PMID:20659230 PMID:21910007 PMID:30408459 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
decreases activity |
ISO |
Simvastatin results in decreased activity of PTK2 protein |
CTD |
PMID:17428261 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Pxn |
paxillin |
multiple interactions affects localization decreases phosphorylation |
EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of PXN protein]]; Simvastatin inhibits the reaction [AGT protein results in increased phosphorylation of and affects the localization of PXN protein] Simvastatin affects the localization of PXN protein Simvastatin results in decreased phosphorylation of PXN protein |
CTD |
PMID:22306966 |
|
NCBI chr12:41,060,791...41,107,952
Ensembl chr12:41,060,791...41,107,931
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions affects localization increases expression decreases activity decreases expression increases activity |
ISO EXP |
Cholesterol inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RAC1 protein]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]]; Simvastatin affects the localization of and results in decreased activity of RAC1 protein; Simvastatin inhibits the reaction [AGT results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased activity of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased localization of RAC1 protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased prenylation of RAC1 protein] Simvastatin affects the localization of RAC1 protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of RAC1 protein] Simvastatin results in decreased activity of RAC1 protein Simvastatin results in decreased expression of RAC1 Simvastatin results in increased activity of RAC1 protein |
CTD |
PMID:16698853 PMID:17169357 PMID:17303772 PMID:17513949 PMID:18625914 PMID:19332549 PMID:19360310 PMID:20045437 PMID:21334995 More...
|
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Rac2 |
Rac family small GTPase 2 |
affects localization decreases activity |
ISO |
Simvastatin affects the localization of RAC2 protein Simvastatin results in decreased activity of RAC2 protein |
CTD |
PMID:17169357 PMID:20045437 |
|
NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720
|
|
G |
Rac3 |
Rac family small GTPase 3 |
affects localization |
ISO |
Simvastatin affects the localization of RAC3 protein |
CTD |
PMID:20045437 |
|
NCBI chr10:106,002,808...106,005,243
Ensembl chr10:105,993,087...106,005,260
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases activity multiple interactions |
ISO EXP |
Simvastatin results in decreased activity of RAF1 protein Simvastatin inhibits the reaction [Streptozocin results in increased expression of RAF1 protein] |
CTD |
PMID:18569938 PMID:19360310 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
decreases prenylation multiple interactions decreases geranoylation decreases expression |
ISO |
Simvastatin results in decreased prenylation of RAP1A protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of RAP1A protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RAP1A protein Simvastatin results in decreased expression of RAP1A protein alternative form |
CTD |
PMID:20018177 PMID:22120639 PMID:25578243 PMID:37956312 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rasgrf1 |
RAS protein-specific guanine nucleotide-releasing factor 1 |
affects phosphorylation affects localization |
ISO |
Simvastatin affects the phosphorylation of RASGRF1 protein Simvastatin affects the localization of RASGRF1 protein |
CTD |
PMID:20417880 |
|
NCBI chr 8:90,445,154...90,574,274
Ensembl chr 8:90,445,154...90,574,269
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO EXP |
Simvastatin results in decreased phosphorylation of RB1 protein |
CTD |
PMID:17928568 PMID:18804536 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases localization decreases localization decreases expression |
ISO EXP |
artemisinin inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; artemisinin inhibits the reaction [Simvastatin results in increased localization of RELA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; parthenolide inhibits the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; parthenolide inhibits the reaction [Simvastatin results in increased localization of RELA protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of and results in increased activity of RELA protein]; Simvastatin promotes the reaction [Doxorubicin results in increased localization of RELA protein]; Simvastatin results in increased localization of and results in increased activity of RELA protein [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]]; Simvastatin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Simvastatin inhibits the reaction [IL1A results in increased localization of RELA protein]; Simvastatin inhibits the reaction [Smoke analog results in increased phosphorylation of RELA protein] [[Simvastatin co-treated with Lipopolysaccharides] results in increased expression of HMOX1 protein] which affects the localization of RELA protein; Homocysteine inhibits the reaction [Simvastatin results in decreased expression of RELA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]; Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]; Simvastatin promotes the reaction [IFNG promotes the reaction [RELA binds to CD40 promoter]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of [RELA protein binds to NFKB1 protein]]]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein modified form]] Simvastatin results in decreased localization of RELA protein Simvastatin results in decreased expression of RELA mRNA; Simvastatin results in decreased expression of RELA protein |
CTD |
PMID:12753293 PMID:15705589 PMID:16414398 PMID:17038636 PMID:17075836 PMID:17277159 PMID:17507688 PMID:18073186 PMID:18463201 PMID:18540024 PMID:18791746 PMID:19299917 PMID:21465237 PMID:21764683 PMID:21910007 PMID:21925249 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ret |
ret proto-oncogene |
multiple interactions |
ISO |
[Hexachlorocyclohexane co-treated with Aldrin co-treated with Dieldrin co-treated with Endrin co-treated with Dichlorodiphenyl Dichloroethylene co-treated with Dichlorodiphenyldichloroethane co-treated with DDT co-treated with Simvastatin] results in decreased expression of RET mRNA |
CTD |
PMID:28263720 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Retn |
resistin |
multiple interactions |
ISO |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein]]; Simvastatin inhibits the reaction [CRP results in increased expression of RETN mRNA]; Simvastatin inhibits the reaction [CRP results in increased secretion of RETN protein] |
CTD |
PMID:18023360 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rfc5 |
replication factor C subunit 5 |
decreases expression |
ISO |
Simvastatin results in decreased expression of RFC5 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
increases expression |
ISO |
Simvastatin results in increased expression of RGS2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions decreases activity decreases expression increases expression increases localization affects localization decreases prenylation |
ISO EXP |
farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeraniol inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin affects the localization of and results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased activity of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased localization of RHOA protein]; MVK gene mutant form promotes the reaction [Simvastatin results in decreased geranoylation of and affects the localization of RHOA protein]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of NFKB1 protein]; RHOA protein affects the reaction [Simvastatin results in increased localization of and results in increased activity of RELA protein]; Simvastatin affects the localization of and results in decreased activity of RHOA protein; Simvastatin inhibits the reaction [geranylgeranyl pyrophosphate affects the localization of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in decreased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin results in decreased localization of and results in decreased activity of RHOA protein; Simvastatin results in increased localization of and results in decreased prenylation of RHOA protein geranylgeraniol inhibits the reaction [Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RHOA protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of RHOA]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R12A protein]]; Simvastatin inhibits the reaction [Phenylephrine promotes the reaction [RHOA protein results in increased phosphorylation of PPP1R14A protein]]; Simvastatin inhibits the reaction [Phenylephrine results in increased activity of RHOA protein]; Simvastatin results in decreased geranoylation of and results in decreased prenylation of RHOA protein Simvastatin results in decreased expression of RHOA; Simvastatin results in decreased expression of RHOA protein Simvastatin results in increased expression of RHOA mRNA farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein] Simvastatin results in increased expression of RHOA protein Simvastatin affects the localization of RHOA protein Simvastatin results in decreased prenylation of RHOA protein |
CTD |
PMID:12477733 PMID:14630613 PMID:15200425 PMID:16005304 PMID:16470222 PMID:16698853 PMID:16740276 PMID:17075836 PMID:17560598 PMID:18031796 PMID:18310456 PMID:18463201 PMID:18625202 PMID:18625914 PMID:18981156 PMID:19024099 PMID:19659652 PMID:20045437 PMID:21124329 PMID:21257924 PMID:24449418 More...
|
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhoc |
ras homolog family member C |
increases expression |
ISO |
Simvastatin results in increased expression of RHOC mRNA |
CTD |
PMID:14630613 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; [Simvastatin co-treated with Metformin] results in increased expression of RIPK1 protein; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]] |
CTD |
PMID:25412314 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
multiple interactions |
ISO |
[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]; necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]; RIPK3 protein affects the reaction [necrostatin-1 inhibits the reaction [[Simvastatin co-treated with Metformin] promotes the reaction [RIPK3 protein binds to RIPK1 protein]]] |
CTD |
PMID:25412314 |
|
NCBI chr15:29,283,153...29,292,107
Ensembl chr15:29,283,145...29,292,121
|
|
G |
Rorc |
RAR-related orphan receptor C |
multiple interactions decreases expression |
ISO |
IFNG affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL27 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; IL4 affects the reaction [Simvastatin results in decreased expression of RORC mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of RORC mRNA] |
CTD |
PMID:18453621 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Rpl39 |
ribosomal protein L39 |
increases expression |
ISO |
Simvastatin results in increased expression of RPL39 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692 Ensembl chr X:6,326,330...6,326,692
|
|
G |
Rps10 |
ribosomal protein S10 |
increases expression |
ISO |
Simvastatin results in increased expression of RPS10 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr20:5,694,313...5,698,922
Ensembl chr20:5,694,313...5,699,044 Ensembl chr 6:5,694,313...5,699,044
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions decreases phosphorylation |
ISO |
IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6 protein] |
CTD |
PMID:27734117 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases phosphorylation |
ISO |
FST protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein]; IGF1 protein inhibits the reaction [Simvastatin results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:27734117 PMID:33034787 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
RT1-A2 |
RT1 class Ia, locus A2 |
affects expression |
ISO |
Simvastatin affects the expression of HLA-E mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,870,939...4,910,183
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Simvastatin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,596,558...4,602,201
Ensembl chr20:4,596,559...4,607,597
|
|
G |
RT1-CE5 |
RT1 class I, locus CE5 |
affects expression |
ISO |
Simvastatin affects the expression of HLA-F mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:3,403,418...3,479,476
|
|
G |
RT1-Da |
RT1 class II, locus Da |
multiple interactions |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of HLA-DRA protein] |
CTD |
PMID:11219190 |
|
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
|
|
G |
RT1-DMa |
RT1 class II, locus DMa |
decreases expression |
EXP |
Simvastatin results in decreased expression of RT1-DMA mRNA |
CTD |
PMID:16414398 |
|
NCBI chr20:4,707,028...4,710,432
Ensembl chr20:4,707,028...4,710,432
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of RUNX2 DKK1 inhibits the reaction [Simvastatin results in increased expression of RUNX2 mRNA]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; Simvastatin inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]] |
CTD |
PMID:18310456 PMID:20381859 PMID:20417880 PMID:22058016 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Ryr2 |
ryanodine receptor 2 |
increases expression |
EXP |
Simvastatin results in increased expression of RYR2 mRNA; Simvastatin results in increased expression of RYR2 protein |
CTD |
PMID:15916736 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of S100A6 mRNA Simvastatin results in increased expression of and results in increased localization of S100A6 protein Simvastatin results in increased expression of S100A6 mRNA; Simvastatin results in increased expression of S100A6 protein |
CTD |
PMID:14973129 PMID:17428261 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
Simvastatin results in increased expression of S100A8 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Simvastatin results in increased expression of S100A9 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
increases expression |
ISO |
Simvastatin results in increased expression of S1PR1 mRNA |
CTD |
PMID:18612546 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
increases expression decreases expression |
ISO |
Simvastatin results in increased expression of S1PR3 mRNA Simvastatin results in decreased expression of S1PR3 mRNA |
CTD |
PMID:18612546 PMID:18981156 |
|
NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505
|
|
G |
Scap |
SREBF chaperone |
affects response to substance |
ISO |
SCAP polymorphism affects the susceptibility to Simvastatin |
CTD |
PMID:16158080 |
|
NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions increases expression |
ISO EXP |
PPARA mutant form inhibits the reaction [Simvastatin results in increased expression of SCARB1]; RHOA inhibits the reaction [Simvastatin results in increased expression of SCARB1] Simvastatin results in increased expression of SCARB1; Simvastatin results in increased expression of SCARB1 mRNA; Simvastatin results in increased expression of SCARB1 protein [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SCARB1 mRNA; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 mRNA]; Simvastatin inhibits the reaction [Dietary Fats results in decreased expression of SCARB1 protein] |
CTD |
PMID:18981156 PMID:20025956 PMID:21241519 PMID:25055962 PMID:33383043 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sdc1 |
syndecan 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of SDC1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Sdc4 |
syndecan 4 |
decreases expression |
EXP |
Simvastatin results in decreased expression of SDC4 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 3:153,154,888...153,173,576
Ensembl chr 3:153,154,896...153,173,580
|
|
G |
Sele |
selectin E |
multiple interactions decreases expression affects expression |
ISO |
farnesyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE mRNA]; Simvastatin promotes the reaction [IL1B protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of SELE protein modified form] Simvastatin affects the expression of SELE protein |
CTD |
PMID:10946302 PMID:14602771 PMID:16740276 PMID:21994025 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selp |
selectin P |
multiple interactions decreases expression |
EXP |
Simvastatin inhibits the reaction [staphylococcal alpha-toxin results in increased expression of SELP protein] Simvastatin results in decreased expression of SELP mRNA |
CTD |
PMID:12379581 PMID:16414398 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression multiple interactions decreases activity decreases secretion |
ISO EXP |
Simvastatin results in decreased expression of SERPINE1 mRNA; Simvastatin results in decreased expression of SERPINE1 protein [Simvastatin co-treated with Dexamethasone] results in increased secretion of SERPINE1 protein Simvastatin results in decreased activity of SERPINE1 protein Simvastatin results in decreased secretion of SERPINE1 protein |
CTD |
PMID:16375908 PMID:16414398 PMID:17513194 PMID:21524281 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
increases expression |
ISO |
Simvastatin results in increased expression of SESN2 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sesn3 |
sestrin 3 |
decreases expression |
ISO |
Simvastatin results in decreased expression of SESN3 mRNA |
CTD |
PMID:20883752 |
|
NCBI chr 8:11,133,822...11,189,436
Ensembl chr 8:11,133,678...11,185,842
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions |
ISO |
[Simvastatin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; SGK2 mutant form inhibits the reaction [[Simvastatin co-treated with NR1I2 protein] results in increased secretion of Glucose]; Simvastatin promotes the reaction [NR1I2 protein binds to SGK2 promoter] |
CTD |
PMID:24204015 |
|
NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:151,644,102...151,669,480
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc38a4 |
solute carrier family 38, member 4 |
increases expression |
ISO |
Simvastatin results in increased expression of SLC38A4 mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:128,144,807...128,202,995
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
increases activity |
ISO |
Simvastatin results in increased activity of SLC6A4 protein |
CTD |
PMID:15740995 |
|
NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384
|
|
G |
Smad1 |
SMAD family member 1 |
multiple interactions increases expression increases phosphorylation |
ISO |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]] Simvastatin results in increased expression of SMAD1 mRNA Simvastatin results in increased phosphorylation of SMAD1 protein |
CTD |
PMID:18310456 PMID:20417880 |
|
NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651
|
|
G |
Smad2 |
SMAD family member 2 |
decreases phosphorylation increases expression increases phosphorylation multiple interactions |
EXP ISO |
Simvastatin results in decreased phosphorylation of SMAD2 protein Simvastatin results in increased expression of SMAD2 mRNA Simvastatin results in increased phosphorylation of SMAD2 protein FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:18310456 PMID:19659652 PMID:33034787 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
increases expression decreases phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
Simvastatin results in increased expression of SMAD3 mRNA Simvastatin results in decreased phosphorylation of SMAD3 protein Simvastatin results in increased phosphorylation of SMAD3 protein FST protein inhibits the reaction [Simvastatin results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:18310456 PMID:19659652 PMID:33034787 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Smad5 |
SMAD family member 5 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]] |
CTD |
PMID:18310456 |
|
NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634
|
|
G |
Smad9 |
SMAD family member 9 |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]] |
CTD |
PMID:18310456 |
|
NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307
|
|
G |
Snx17 |
sorting nexin 17 |
decreases expression multiple interactions |
EXP |
Simvastatin results in decreased expression of SNX17 mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of SNX17 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 6:25,177,528...25,183,001
Ensembl chr 6:25,177,391...25,183,030
|
|
G |
Soat1 |
sterol O-acyltransferase 1 |
increases expression |
EXP |
Simvastatin results in increased expression of SOAT1 mRNA |
CTD |
PMID:12056585 |
|
NCBI chr13:68,552,274...68,597,529
Ensembl chr13:68,552,317...68,597,494
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
ISO |
Simvastatin results in increased expression of SOCS3 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Socs4 |
suppressor of cytokine signaling 4 |
increases expression |
ISO |
Simvastatin results in increased expression of SOCS4 mRNA; Simvastatin results in increased expression of SOCS4 protein |
CTD |
PMID:19262002 |
|
NCBI chr15:20,523,406...20,537,889
Ensembl chr15:20,523,183...20,542,494
|
|
G |
Socs7 |
suppressor of cytokine signaling 7 |
increases expression |
ISO |
Simvastatin results in increased expression of SOCS7 mRNA |
CTD |
PMID:18453621 |
|
NCBI chr10:82,352,159...82,388,829
Ensembl chr10:82,351,680...82,388,830
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of SOD2 mRNA |
CTD |
PMID:16414398 PMID:20883752 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
EXP |
Simvastatin inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [SP1 binds to COL1A1 promoter] |
CTD |
PMID:16575855 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Simvastatin results in increased expression of SP7 protein]; DKK1 inhibits the reaction [Simvastatin results in increased expression of SP7 mRNA] Simvastatin results in increased expression of SP7; Simvastatin results in increased expression of SP7 mRNA; Simvastatin results in increased expression of SP7 protein |
CTD |
PMID:20564244 PMID:22058016 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spon2 |
spondin 2 |
increases expression |
ISO |
Simvastatin results in increased expression of SPON2 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr14:77,505,695...77,518,001
Ensembl chr14:77,511,901...77,517,996
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression increases expression |
ISO EXP |
Simvastatin results in decreased expression of SPP1 mRNA Simvastatin results in increased expression of SPP1 protein |
CTD |
PMID:12914771 PMID:14601315 PMID:21076490 PMID:21109955 PMID:22058016 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein; Chloroquine inhibits the reaction [[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:25412314 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases localization decreases expression |
ISO EXP |
Simvastatin results in increased localization of SREBF1 protein Simvastatin results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17655842 PMID:25055962 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions increases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter]]; Simvastatin promotes the reaction [SREBF2 protein binds to PON1 promoter] Simvastatin results in increased expression of SREBF2 protein modified form Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of SREBF2 mRNA]; Simvastatin results in increased activity of and results in increased localization of SREBF2 protein |
CTD |
PMID:12056585 PMID:14500290 PMID:20018177 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
EXP |
Simvastatin results in increased expression of STAR mRNA [Simvastatin co-treated with di-n-pentyl phthalate] results in decreased expression of STAR mRNA |
CTD |
PMID:24524197 PMID:25055962 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions decreases expression decreases activity decreases phosphorylation |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT1 protein]; Simvastatin inhibits the reaction [IFNG results in increased expression of STAT1 mRNA] Simvastatin results in decreased expression of STAT1 mRNA Simvastatin results in decreased activity of STAT1 protein geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin results in decreased expression of STAT1 protein]; Simvastatin inhibits the reaction [IFNG promotes the reaction [STAT1 binds to CD40 promoter]]; Simvastatin inhibits the reaction [IFNG results in increased phosphorylation of STAT1 protein] Simvastatin results in decreased expression of STAT1 mRNA; Simvastatin results in decreased expression of STAT1 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT1 protein] |
CTD |
PMID:16534557 PMID:17507688 PMID:18453621 PMID:19886038 PMID:21268089 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases activity multiple interactions affects expression decreases phosphorylation |
ISO EXP |
Simvastatin results in decreased activity of STAT3 protein Mevalonic Acid inhibits the reaction [Simvastatin results in decreased phosphorylation of STAT3 protein] Simvastatin affects the expression of STAT3 protein Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein modified form]; Simvastatin inhibits the reaction [CTF1 results in increased expression of STAT3 protein]; Simvastatin inhibits the reaction [CTF1 results in increased phosphorylation of STAT3 protein]; Simvastatin inhibits the reaction [Streptozocin results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:16534557 PMID:17507688 PMID:18400235 PMID:18453621 PMID:19100119 PMID:19886038 PMID:20821229 PMID:21910007 More...
|
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
affects expression |
ISO |
Simvastatin affects the expression of STAT5A protein |
CTD |
PMID:17507688 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
affects expression |
ISO |
Simvastatin affects the expression of STAT6 protein |
CTD |
PMID:17507688 |
|
NCBI chr 7:63,480,229...63,497,551
Ensembl chr 7:63,479,642...63,498,495
|
|
G |
Stk11 |
serine/threonine kinase 11 |
increases phosphorylation |
ISO |
Simvastatin results in increased phosphorylation of STK11 protein |
CTD |
PMID:19332549 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tab1 |
TGF-beta activated kinase 1/MAP3K7 binding protein 1 |
multiple interactions |
ISO |
Simvastatin results in decreased activity of [MAP3K7 protein co-treated with TAB1 protein] |
CTD |
PMID:17277159 |
|
NCBI chr 7:111,675,829...111,707,058
Ensembl chr 7:111,686,371...111,707,058
|
|
G |
Tank |
TRAF family member-associated NFKB activator |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Simvastatin] results in increased expression of TANK mRNA |
CTD |
PMID:15665042 |
|
NCBI chr 3:46,114,230...46,190,270
Ensembl chr 3:46,114,274...46,190,264
|
|
G |
Tbxas1 |
thromboxane A synthase 1 |
decreases expression increases expression |
EXP |
Simvastatin results in decreased expression of TBXAS1 mRNA Simvastatin results in increased expression of TBXAS1 mRNA |
CTD |
PMID:16414398 PMID:20659230 |
|
NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions increases expression |
EXP |
Simvastatin inhibits the reaction [Streptozocin results in increased expression of TEK mRNA]; Simvastatin results in increased expression of and results in increased activity of TEK protein Simvastatin results in increased expression of TEK; Simvastatin results in increased expression of TEK mRNA |
CTD |
PMID:18544044 PMID:20821229 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
Simvastatin inhibits the reaction [TNF results in increased expression of TF] |
CTD |
PMID:12753293 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tfrc |
transferrin receptor |
affects expression |
ISO |
Simvastatin affects the expression of TFRC protein |
CTD |
PMID:16387846 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression increases activity decreases expression |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of ACTA2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 mRNA]; Simvastatin inhibits the reaction [TGFB1 results in increased expression of CCN2 protein] Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein] Simvastatin results in increased expression of TGFB1 mRNA Simvastatin results in increased activity of TGFB1 protein Simvastatin results in decreased expression of TGFB1 mRNA; Simvastatin results in decreased expression of TGFB1 protein |
CTD |
PMID:15298857 PMID:15677772 PMID:15855201 PMID:16320597 PMID:19080365 PMID:19262002 PMID:19659652 PMID:20024970 PMID:20687301 PMID:21844074 More...
|
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions decreases expression |
ISO EXP |
Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TGFBR2 mRNA] Simvastatin results in decreased expression of TGFBR2 mRNA |
CTD |
PMID:16320597 PMID:16373842 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Thbd |
thrombomodulin |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of THBD mRNA; Simvastatin results in increased expression of THBD protein Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of THBD mRNA] |
CTD |
PMID:14630613 PMID:16375908 PMID:20493886 PMID:20737288 |
|
NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
ISO |
Simvastatin results in decreased expression of THBS1 mRNA |
CTD |
PMID:17428261 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions decreases expression |
EXP |
Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Monocrotaline results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16414398 PMID:20137537 PMID:22022327 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions decreases expression |
EXP |
Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP2 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:20137537 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression multiple interactions |
ISO |
Simvastatin results in increased expression of TLR2 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 protein] |
CTD |
PMID:16387846 PMID:16443229 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression decreases expression multiple interactions |
ISO EXP |
Simvastatin results in increased expression of TLR4 protein Simvastatin results in decreased expression of TLR4 mRNA; Simvastatin results in decreased expression of TLR4 protein Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein] |
CTD |
PMID:16387846 PMID:16443229 PMID:19166837 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
increases expression |
EXP |
Simvastatin results in increased expression of TM7SF2 mRNA |
CTD |
PMID:25055962 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tnc |
tenascin C |
decreases expression |
EXP |
Simvastatin results in decreased expression of TNC mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression decreases activity decreases expression increases secretion decreases secretion affects secretion |
ISO EXP |
geranylgeraniol inhibits the reaction [Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCL4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]]; Simvastatin inhibits the reaction [CCN1 results in increased expression of TNF]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF protein results in increased activity of [NFKB1 protein binds to RELA protein]]; Simvastatin inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of and affects the localization of RELA protein]; Simvastatin inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in decreased expression of PLAT]; Simvastatin inhibits the reaction [TNF results in increased activity of RHOA protein]; Simvastatin inhibits the reaction [TNF results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased expression of CCL2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CCR4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL8 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ICAM1]; Simvastatin inhibits the reaction [TNF results in increased expression of IL6 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGAL]; Simvastatin inhibits the reaction [TNF results in increased expression of ITGB2]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of PTGS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of TF]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased localization of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased localization of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased localization of RELA protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL2 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of CCL4 mRNA]; Simvastatin inhibits the reaction [TNF results in increased secretion of CXCL8 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL1B protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of IL6 protein]; Simvastatin inhibits the reaction [TNF results in increased secretion of MMP9 protein]; Simvastatin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin promotes the reaction [TNF protein results in increased expression of SELE protein]; Simvastatin promotes the reaction [TNF results in increased expression of MMP9 mRNA]; Simvastatin promotes the reaction [TNF results in increased expression of PPARA] Simvastatin results in increased expression of TNF mRNA 1-propyl-8-(4-sulfophenyl)xanthine inhibits the reaction [Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]]; Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]]; Simvastatin inhibits the reaction [Acetic Acid results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Acrolein results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNF protein]; Simvastatin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Simvastatin inhibits the reaction [Oxygen deficiency results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [TNF results in decreased expression of NOS2 protein]; Simvastatin inhibits the reaction [TNF results in increased expression of NOS2 mRNA] Simvastatin results in decreased activity of TNF; Simvastatin results in decreased activity of TNF protein farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]]; farnesyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Guanidines inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]]; Simvastatin inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Simvastatin inhibits the reaction [TNF affects the localization of RHOA protein]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD1 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD5 protein]]; Simvastatin inhibits the reaction [TNF inhibits the reaction [BMP2 results in increased phosphorylation of SMAD9 protein]]; Simvastatin inhibits the reaction [TNF protein inhibits the reaction [BMP2 results in increased expression of RUNX2 mRNA]]; Simvastatin inhibits the reaction [TNF results in increased expression of CXCL15 mRNA]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK1 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK3 protein]; Simvastatin inhibits the reaction [TNF results in increased phosphorylation of MAPK8 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased abundance of Nitric Oxide]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of IL6 protein]; Simvastatin promotes the reaction [[Lipopolysaccharides co-treated with TNF] results in increased expression of NOS2 mRNA]; zinc protoporphyrin inhibits the reaction [Simvastatin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] Simvastatin results in decreased expression of TNF mRNA; Simvastatin results in decreased expression of TNF protein Simvastatin results in increased secretion of TNF protein Simvastatin results in decreased secretion of TNF protein Simvastatin affects the secretion of TNF protein |
CTD |
PMID:10946302 PMID:12117737 PMID:12615677 PMID:12753293 PMID:12829860 PMID:12963647 PMID:15187114 PMID:15234187 PMID:15537504 PMID:15705589 PMID:15883752 PMID:16321392 PMID:16387846 PMID:16443229 PMID:16511915 PMID:16740276 PMID:17075836 PMID:17169357 PMID:17178392 PMID:17277159 PMID:17560598 PMID:17729120 PMID:17901590 PMID:18047562 PMID:18310456 PMID:18504409 PMID:19001041 PMID:19024099 PMID:19080365 PMID:19166837 PMID:20126887 PMID:20191585 PMID:20359552 PMID:20863785 PMID:21910007 PMID:21925249 PMID:21994025 PMID:22305382 PMID:30408459 PMID:33774062 PMID:35762198 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
Simvastatin results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:21431270 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
decreases expression |
ISO |
Simvastatin results in decreased expression of TNFRSF1A mRNA |
CTD |
PMID:18310456 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
decreases expression |
ISO |
Simvastatin results in decreased expression of TNFRSF1B mRNA |
CTD |
PMID:18310456 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfrsf4 |
TNF receptor superfamily member 4 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFRSF4 protein] Simvastatin results in decreased expression of TNFRSF4 mRNA; Simvastatin results in decreased expression of TNFRSF4 protein |
CTD |
PMID:19589242 |
|
NCBI chr 5:166,606,909...166,609,599
Ensembl chr 5:166,606,909...166,609,599
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases response to substance |
ISO |
[Simvastatin co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; geranylgeranyl pyrophosphate inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; Mevalonic Acid inhibits the reaction [TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein]]; Simvastatin promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]; TNFSF10 protein promotes the reaction [Simvastatin results in increased cleavage of PARP1 protein] TNFSF10 protein results in increased susceptibility to Simvastatin |
CTD |
PMID:21910007 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
multiple interactions decreases expression |
ISO |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein]]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 mRNA]; Simvastatin inhibits the reaction [IFNG results in increased expression of TNFSF4 protein] Simvastatin results in decreased expression of TNFSF4 mRNA; Simvastatin results in decreased expression of TNFSF4 protein |
CTD |
PMID:19589242 |
|
NCBI chr13:73,723,329...73,746,809
Ensembl chr13:73,723,329...73,746,788
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
Nitroarginine inhibits the reaction [Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein]]; Simvastatin inhibits the reaction [Cyclophosphamide results in increased expression of TNNI3 protein] |
CTD |
PMID:35762198 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation increases expression |
ISO EXP |
pifithrin inhibits the reaction [Simvastatin results in increased expression of TP53 protein]; Simvastatin promotes the reaction [Benzo(a)pyrene promotes the reaction [TP53 protein binds to MDM2 protein]]; Simvastatin promotes the reaction [TP53 protein binds to CD44 promoter]; Simvastatin results in increased expression of and results in increased phosphorylation of TP53 protein Simvastatin results in increased phosphorylation of TP53 protein Simvastatin results in increased expression of TP53 mRNA; Simvastatin results in increased expression of TP53 mutant form; Simvastatin results in increased expression of TP53 protein |
CTD |
PMID:15625077 PMID:18804536 PMID:20045437 PMID:21199873 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of TPT1 protein |
CTD |
PMID:20217863 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
decreases expression |
ISO |
Simvastatin results in decreased expression of TRADD mRNA |
CTD |
PMID:17277159 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
decreases expression |
ISO |
Simvastatin results in decreased expression of TRAF2 mRNA |
CTD |
PMID:17277159 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Trim63 |
tripartite motif containing 63 |
increases expression multiple interactions |
EXP ISO |
Simvastatin results in increased expression of TRIM63 mRNA FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA]; FST protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 protein]; IGF1 protein inhibits the reaction [Simvastatin results in increased expression of TRIM63 mRNA] Simvastatin results in increased expression of TRIM63 mRNA; Simvastatin results in increased expression of TRIM63 protein |
CTD |
PMID:19001041 PMID:27734117 PMID:33034787 |
|
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:16414398 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression |
ISO |
Simvastatin results in decreased expression of TYMS mRNA; Simvastatin results in decreased expression of TYMS protein |
CTD |
PMID:17428261 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
decreases phosphorylation |
ISO |
Simvastatin results in decreased phosphorylation of VASP protein |
CTD |
PMID:19332549 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions decreases expression |
ISO EXP |
Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]]; Simvastatin inhibits the reaction [CD40LG results in increased expression of VCAM1 mRNA]; Simvastatin inhibits the reaction [TNF results in increased expression of VCAM1 mRNA]; Simvastatin promotes the reaction [[Ethinyl Estradiol co-treated with Desogestrel] results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [ethinyl estradiol-desogestrel combination results in decreased expression of VCAM1 protein]; Simvastatin promotes the reaction [IL1B protein results in increased expression of VCAM1 protein]; Vitamin E inhibits the reaction [Simvastatin results in decreased expression of VCAM1 protein modified form] Simvastatin results in decreased expression of VCAM1 mRNA; Simvastatin results in decreased expression of VCAM1 protein; Simvastatin results in decreased expression of VCAM1 protein modified form |
CTD |
PMID:10946302 PMID:14602771 PMID:15234187 PMID:17105841 PMID:17169357 PMID:18269829 PMID:18309148 PMID:20863785 PMID:21874229 PMID:22245985 More...
|
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vcl |
vinculin |
affects localization |
EXP |
Simvastatin affects the localization of VCL protein |
CTD |
PMID:22306966 |
|
NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of VDAC1 protein |
CTD |
PMID:20217863 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
increases expression |
ISO |
Simvastatin results in increased expression of VDR mRNA |
CTD |
PMID:19262002 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression increases expression increases secretion |
ISO EXP |
geranylgeranyl pyrophosphate inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; HIF1A mutant form inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]]; Mevalonic Acid inhibits the reaction [Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]]; Mevalonic Acid inhibits the reaction [Simvastatin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [IL6 results in increased expression of VEGFA protein]; Simvastatin inhibits the reaction [TNF protein results in increased expression of VEGFA protein] Simvastatin results in decreased expression of VEGFA protein Simvastatin results in increased expression of VEGFA; Simvastatin results in increased expression of VEGFA mRNA Simvastatin results in increased secretion of VEGFA protein Simvastatin results in increased expression of VEGFA mRNA; Simvastatin results in increased expression of VEGFA protein Simvastatin inhibits the reaction [Glucose results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]; Simvastatin inhibits the reaction [Streptozocin results in increased expression of VEGFA protein] |
CTD |
PMID:15572054 PMID:16424782 PMID:17277159 PMID:18316203 PMID:18356691 PMID:18569938 PMID:20381859 PMID:20687301 PMID:20821229 PMID:21211366 More...
|
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
decreases expression |
ISO EXP |
Simvastatin results in decreased expression of VIM protein |
CTD |
PMID:14973129 PMID:15855201 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Vwf |
von Willebrand factor |
increases expression |
EXP |
Simvastatin results in increased expression of VWF mRNA; Simvastatin results in increased expression of VWF protein |
CTD |
PMID:19109527 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
G |
Wnt4 |
Wnt family member 4 |
multiple interactions increases expression |
EXP |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT4 mRNA] Simvastatin results in increased expression of WNT4 protein |
CTD |
PMID:18004065 |
|
NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions increases expression |
EXP |
Simvastatin inhibits the reaction [Glucose results in decreased expression of WNT5A mRNA] Simvastatin results in increased expression of WNT5A mRNA; Simvastatin results in increased expression of WNT5A protein |
CTD |
PMID:18004065 PMID:19968183 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
EXP |
Simvastatin results in decreased expression of XBP1 protein |
CTD |
PMID:18807172 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
Simvastatin results in decreased expression of XIAP mRNA; Simvastatin results in decreased expression of XIAP protein |
CTD |
PMID:19262002 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|